 ,,,,,,,,,,Phys-Chem,,,,,,,Caco2 Ellinger,,,,Vero-E6 Zaliani ,,,,Vero-E6 Touret,HRCE Heiser,3CLPro Kuzikov,,Vero-E6 Riva,Bakowski,,,,SARS-CoV Pseudotyped particle entry Vero E6 - NCATS and PubChem (AID:1479145),,,,,SARS-CoV Pseudotyped particle entry Vero E6 (Tox counterscreen)- NCATS and PubChem (AID:1479150),,,,,,MERS Pseudotyped particle entry Huh7 - NCATS and PubChem (AID:1479149),,,,,MERS Pseudotyped particle entry Huh7 (Tox counterscreen) - NCATS and PubChem (AID:1479147),,,,,,"SARS-CoV-2 cytopathic effect (CPE) - NCATS, PubChem (AID:1508606) and Chen",,,,,,,"SARS-CoV-2 cytopathic effect (CPE)(Tox counterscreen) - NCATS, PubChem (AID:1508605) and Chen",,,,,,,,Activity ranks,PK/PD,,,,,,,Red Flags,,,,,,
Name,Indication (1),Pathway (1),Target (1),MOA(1),EC50 value,IC50 value,pIC50 value,type,SMILES,MW,logP,HBA,HBD,RotBonds,PSA,NoChiralCentres,% inhibition,IC50 (nM),CC50 (nM),Caco2 Selectivity index,% inhibition,IC50 (nM),CC50 (nM),Selectivity index,Inhibition index,Hit score,% inihibition,IC50 (nM),%Viral inhibition,Calu3 EC50 GeoMean (µM),HeLa-ACE2 EC50 GeoMean (µM),HEK293T CC50 GeoMean (µM),HepG2 CC50 GeoMean (µM),AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,Tox,AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,Tox,AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,CPE EC50 (uM),CPE % Efficacy,AC50 (μM),AUC,"Potency (μM) Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.","Efficacy (%) Maximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.",Activity,Tox,Cytotox CC50 (uM),% Cytotox,Rank score,Administration route,Cmax,protein-binding,Vd (Volume of distribution),CL (Clearance),t_half (Half-life),BA (Bioavailability),Drug interactions,Contraindications,Pregnancy concerns,Breast feeding,Side effects,Predicted CAD (Cationic amphiphile) induced phospholipidosis,PAINS
Tolterodine (tartrate),"Urinary antispasmodics, Overactive bladder agent","Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",acetylcholine receptor antagonist,,,8.2006,pIC50,Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)[C@H](O)[C@@H](O)C(=O)O,475.582,3.21882,6,5,10,138.53,3,,,,,,,,,1.165,,,,,,,,,39.81071706,-10.0597169,,,,0,-139.3818361,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.02716049383,Oral,,96.30%,113 ± 26.7L,,1.9-3.7h,,None,Urinary/gastric retention; uncontrolled narrow angle glaucome;,Category B3,Not recommended,NA,,
Palonosetron (Hydrochloride),Anti-emetic,Serotonergic synapse,HTR3A,serotonin receptor antagonist,,,,Ki,Cl.O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,332.875,3.0783,2,0,1,23.55,4,57.4,,,,0.02,,,,0.9614,0.1883,-0.9864,,,,,,,0,-37.19548142,0,0,Inactive,0,0.9017623453,0,0,Inactive,Inactive,28.18382931,-83.07818418,28.1838,42.755,Inconclusive,0,-12.23620792,0,0,Inactive,Inactive,0,-1.975933887,,,,,,0,-30.35097602,,,,,,,0.2313175473,Oral,,62%,8.3 ± 2.5 L/kg,160 ± 35mL/h/kg,~40h,,Apomorphine,"Hypersensitivity; When co-administered with apomorphine, causes hypotension and loss of consciousness",Category B1,Use with caution,NA,,
Dapoxetine (hydrochloride),Antidepressant,Serotonergic synapse,"HTR1A, HTR1B, HTR2C, SLC6A4",selective serotonin reuptake inhibitor (SSRI),,,,,CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1.Cl,341.882,5.3334,2,0,6,12.47,1,65.1,,,,0.09,,,,,,5.583,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.2358875108,,,,,,1-2h,,NA,NA,Category C,Not recommended,None,,
Solifenacin (Succinate),Attention Deficit Hyperactivity Disorder Agent,Synaptic vesicle cycle,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",acetylcholine receptor antagonist,,,7.197,pIC50,O=C(O)CCC(=O)O.O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,480.561,3.8007,5,2,5,107.38,4,15.21,,,,0.15,,,,,,22.54,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.2886450105,Oral,,93-96%,600L,7-14L/h,33-85h,,Itraconazole; Lefamulin,Hypersensitivity; gastric retension; narrow-angle glaucoma,Category B3,Not recommended,NA,,
Indinavir (sulfate),Anti-HIV,Protein biosynthesis,"CYP3A4, CYP3A5, CYP3A7",HIV protease inhibitor,,150,6.824,pIC50,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O.O=S(=O)(O)O,711.882,2.2141,9,6,11,192.63,5,,,,,,,,,0.3816,,,,,,,,,0,-99.34935433,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,6.044445246,0,0,Inactive,0,0.6603335219,0,0,Inactive,Inactive,0,16.6195617,,,,,,0,-22.93077735,,,,,,,0.3074074074,Oral,,60%,,,1.8h,,Alfuzosin; amiodarone; cobicistat; cobimetinib; conivaptan; dihydroergotamine; dihydroergotamine intranasal; eliglustat; elvitegravir/cobicistat/emtricitabine/tenofovir DF; ergoloid mesylates; ergonovine; etravirine; finerenone; flibanserin; irinotecan; irinotecan liposomal; isavuconazonium sulfate; ivabradine; lomitapide; lonafarnib; lovastatin; lurasidone; methylergonovine; naloxegol; regorafenib; salmeterol; simvastatin; St John's Wort; tipranavir; venetoclax; voclosporin,Hypersensitivity,Category B3,Not recommended,None,,
Tiagabine (hydrochloride),Anticonvulsants,GABAergic synapse,SLC6A1,GABA uptake inhibitor,,,6.829,pIC50,Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C.Cl,412.02,5.46664,4,1,6,40.54,1,31.5,,,,0.01,,,,0.2483,,-8.564,,,,,,,3.981071706,-23.56476591,3.9811,37.5546,Inconclusive,0,-6.606118034,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,10.91633539,0,0,Inactive,Inactive,0,-2.59636294,,,,,,0,-33.52579994,,,,,,,0.3642156587,Oral,,96%,,109 mL/min [Healthy subjects],7-9 hours,,None,Hypersensitivity,Category B3,Use with caution,NA,,
Ethambutol (dihydrochloride),Antibacterial (tuberculostatic),NA,,bacterial cell wall synthesis inhibitor,,,6.209,pIC50,CC[C@@H](CO)NCCN[C@@H](CC)CO.Cl.Cl,277.236,0.551,4,4,9,64.52,2,8.87,,,,0.05,,,,,,21.74,,,,,,,0,-86.39508515,0,0,Inactive,0,4.141143292,0,0,Inactive,Inactive,0,5.762307416,0,0,Inactive,0,1.05984262,0,0,Inactive,Inactive,0,-2.452928521,,,,,,0,-16.78227429,,,,,,,0.3850432766,Oral, 2-5 µg/mL,Ethambutol is 20-30% bound to protein in plasma. Data regarding which proteins ethambutol binds to are not readily available,Patients coinfected with tuberculosis and HIV have an estimated ethambutol volume of distribution of 76.2 L,Patients coinfected with tuberculosis and HIV have an estimated ethambutol oral clearance of 77.4 L/h,"Ethambutol has a half life of 3.3 hours in patients with normal renal function. In patients with renal failure, the half life could be 7 hours or longer",75-80%,None,Hypersensitivity; Optic neuritis; changes in vision,Category A,Recommended,NA,,
Telotristat etiprate,Antidiarrheal,"Tryptophan metabolism, Seratonergic synapse",TPH1,tryptophan hydroxylase inhibitor,,,7.796,pIC50,CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1.O=C(O)CNC(=O)c1ccccc1,754.166,5.48962,11,4,12,197.57,2,3.02,,,,0.17,,,,,,8.235,,,,,,,39.81071706,-68.04863548,0,0,Inactive,0,-19.81621671,0,0,Inactive,Inactive,0,4.186659697,0,0,Inactive,0,1.158913405,0,0,Inactive,Inactive,0,13.9536923,,,,,,0,-10.74923334,,,,,,,0.406824053,Oral,,"High plasma protein binding of its active metabolite, Telotristat.",,,4–12 h,,NA,NA,Category B3,Not recommended,NA,,
Pergolide (mesylate),Antiparkinsonian,"Neuroactive ligand-receptor interaction, Dopaminergic synapse","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",dopamine receptor agonist,,,,Ki,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21.CS(=O)(=O)O,410.605,3.7751,4,2,4,73.4,3,1.63,,,,-0.14,,,,1.047,,0.07731,,,,,,,0,-36.7887671,0,0,Inactive,0,0.2036049352,0,0,Inactive,Inactive,39.81071706,-17.85025251,39.8107,49.898,Inconclusive,0,0,0,0,Inactive,Inactive,0,1.585786295,,,,,,0,-18.38445142,,,,,,,0.479682924,Oral,,90%,,,27 h,,NA,NA,Category C,NA,NA,,
Pyrantel (tartrate),Anthelmintic,NA,,"acetylcholine receptor agonist, nicotinic receptor agonist",,,,,CN1CCCN=C1/C=C/c1cccs1.O=C(O)[C@H](O)[C@@H](O)C(=O)O,356.4,0.3727,7,4,5,130.66,2,,,,,,,,,0.1796,,,,,,,,,0,-9.907019226,0,0,Inactive,0,-15.82883637,0,0,Inactive,Inactive,0,-92.44778293,0,0,Inactive,0,-3.029288205,0,0,Inactive,Inactive,0,3.597812835,,,,,,0,-17.98430674,,,,,,,0.4950617284,Oral,,,,,1.75 h,,None,Hypersensitivity; Intestinal obstruction; Hepatic disease,Category B2,Not much information is available,NA,,
Delavirdine (mesylate),Anti-HIV,RNA replication/synthesis,CYP3A4; HIV1,non-nucleoside reverse transcriptase inhibitor,,,7.4437,pIC50,CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1.CS(=O)(=O)O,552.679,2.2211,8,4,6,164.8,0,-1.61,,,,0.21,,,,,,83.7,3990,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,-8.024277089,,,,,,0,-13.59541524,,,,,,,0.4976879046,Oral,,98%,,,5.8 h,,Esomeprazole; Ritonavir; Mirtazapine,NA,Category B3,NA,NA,,
Eletriptan (hydrobromide),"Antimigraine, Vasoconstrictor,","Neuroactive ligand-receptor interaction, Seratonergic synapse","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7",serotonin receptor agonist,,,,Ki,Br.CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,463.441,4.3989,3,1,6,53.17,1,0.96,,,,0.08,,,,,,3.937,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5018496888,Oral,,85%,138L,3.9L/h,4 h,0.5,Almotriptan; bromocriptine; cabergoline; chloramphenicol; cobicistat; dihydroergotamine; dihydroergotamine intranasal; ergoloid mesylates; ergotamine; frovatriptan; lopinavir; methylergonovine; mifepristone; naratriptan; rizatriptan; saquinavir; sumatriptan; sumatriptan intranasal; tipranavir; zolmitriptan,Hypersensitivity; Ischemic coronary artery disease,Category B1,Use with caution,NA,,
Cefuroxime (sodium),Antibacterial,Peptidoglycan biosynthesis,,bacterial cell wall synthesis inhibitor,,2.09E+03,,IC50,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(N)=O)CS[C@H]12)c1ccco1.[Na+],446.373,-4.8667,10,2,7,176.59,2,-2.78,,,,0.11,,,,0.2609,,-3.438,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5107464964,Oral,,50%,,,80mins,0.52,None,Hypersensitivity,Category B1,Use with caution,NA,,
Darifenacin (hydrobromide),Urinary antispasmodics,"Neuroactive ligand-receptor interaction, Cholinergic synapse","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",acetylcholine receptor antagonist,,,,Ki,Br.NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1,507.472,4.5354,3,1,7,55.56,1,-5.74,,,,0.01,,,,0.6317,,14.06,,,,,,,0,-7.468185967,0,0,Inactive,0,-4.063350921,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.9601806211,0,0,Inactive,Inactive,0,-0.6067976444,,,,,,0,-31.74358728,,,,,,,0.5299223763,Oral,,98%,163L,40L/h (Extensive metabolizers; 32L/h (poor metabolizers),13-19 h,15-19%,Eliglustat,Urinary retention; Uncontrolled narrow-angle glaucoma; Severe hepatic impairment; Paralytic ileus; GI or Gu obstruction; Hypersensitivity,Category B3,Use with caution,NA,,
Alogliptin (Benzoate),Antidiabetic,Protein digestion and absorption,DPP4,dipeptidyl peptidase inhibitor,,,8,pIC50,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O.O=C(O)c1ccccc1,461.522,1.77928,8,2,4,134.35,1,-0.02,,,,0.07,,,,,,16.4,,,,,,,0,2.234603,0,0,Inactive,0,-12.51693882,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,,,,,,,,,,,,,,,,0.5315895141,Oral,,20%,417L,9.6 h (Renal); 14.0L/h (Systemic),21 h,1,None,Hypersensitivity; Stevens-johnson syndrome,Category B3,Use with caution,NA,,
(S)-Rasagiline,Antiparkinsonian,"Seratonergic synapse, Dopaminergic synapse","BCL2, MAOB",monoamine oxidase inhibitor,,,8.3979,pIC50,C#CCN[C@H]1CCc2ccccc21,171.243,1.8967,1,1,2,12.03,1,,,,,0,,,,,,19.35,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.55014236,Oral,,88-94%,87L,,3 h,0.36,Apraclonidine; atomoxetine; brimonidine; bupropion; cyproheptadine; desvenlafaxine; deutetrabenazine; dexmethylphenidate; dextroamphetamine; dextromethorphan; ephedrine; fentanyl; fentanyl intranasal; fentanyl transdermal; fentanyl transmucosal; isocarboxazid; levomilnacipran; lisdexamfetamine; meperidine; methadone; methamphetamine; methylphenidate; milnacipran; mirtazapine; ozanimod; phenelzine; phenylephrine PO; procarbazine; pseudoephedrine; safinamide; selegiline; solriamfetol; St John's Wort; tapentadol; tetrabenazine; tramadol; tranylcypromine; vilazodone; vortioxetine,NA,Category B3,Use with caution,NA,,
Erlotinib (Hydrochloride),Antineoplastic,"MAPK signaling pathway, ErbB signaling pathway","EGFR, NR1I2",EGFR inhibitor,,,10.5228,pIC50,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,429.904,3.8269,7,1,10,74.73,0,25.79,,,,-0.22,,,,,,-0.1805,,,,,,,15.84893192,-59.67210683,,,,0,0,,,,,,,,,,,,,,,,0,-11.22576462,,,,,,8.912509381,-99.7611631,,,,,,,0.5534565183,Oral,,93%,232L,,36.2 h,60%; With food 100%,Dexlansoprazole; esomeprazole; lansoprazole; omeprazole; pantoprazole; rabeprazole,None,Category C,Not recommended,NA,,
Anagrelide (hydrochloride),"Thrombocythemia treatment, Platelet aggregation inhibitor",Purine metabolism,PDE3A,phosphodiesterase inhibitor,,,7.086,pIC50,Cl.O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1,292.553,2.3481,3,1,0,44.7,0,3.09,,,,-0.03,,,,,,5.284,,,,,,,0,-35.48479791,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.580106196,0,0,Inactive,Inactive,0,1.516937603,,,,,,0,-6.237992323,,,,,,,0.5538152396,Oral,,,,,1.5-2.5 h,0.7,Goserelin; histrelin; leuprolide; triptorelin,Hepatic imoairement,Category B3,Use with caution,NA,,
Naloxegol (oxalate),Laxative,Neuroactive ligand-receptor interaction,OPRM1,opioid receptor antagonist,,,,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5.O=C(O)C(=O)O,741.828,1.0191,14,4,24,201.37,5,14.12,,,,-0.16,,,,,,13.22,,,,,,,0,10.61971908,0,0,Inactive,0,-0.753420405,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.2028322124,0,0,Inactive,Inactive,0,-0.0227112475,,,,,,0,2.32226964,,,,,,,0.5573271669,Oral,,~4.2%,,68% (feces); 16% (urine),6-11 h,,Abametapir; atazanavir; bosentan; carbamazepine; chloramphenicol; clarithromycin; cobicistat; conivaptan; dabrafenib; darunavir; dexamethasone; elvitegravir/cobicistat/emtricitabine/tenofovir DF; enzalutamide; eslicarbazepine acetate; etravirine; fosamprenavir; fosphenytoin; grapefruit; idelalisib; imatinib; indinavir; isoniazid; itraconazole; ketoconazole; lopinavir; mifepristone; mitotane; nafcillin; nefazodone; nelfinavir; nevirapine; nicardipine; oxcarbazepine; pentobarbital; phenobarbital; phenytoin; posaconazole; primidone; quinidine; ribociclib; rifabutin; rifampin; rifapentine; ritonavir; saquinavir St John's Wort ;tipranavir,Hypersensitivity; GI obstruction,NA,Not recommended,NA,,
Naratriptan (hydrochloride),"Antimigraine, Vasoconstrictor,","Neuroactive ligand-receptor interaction, Seratonergic synapse","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",serotonin receptor agonist,,,,Ki,CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1.Cl,371.934,2.4906,3,2,5,65.2,0,-4.68,,,,0.16,,,,,,3.72,,,,,,,39.81071706,-43.8071261,39.8107,44.6791,Inconclusive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,1.01036248,0,0,Inactive,Inactive,0,-3.71195786,,,,,,0,-14.89597196,,,,,,,0.5814939839,Oral,Peak plasma concentrations after 2-5 hours,28%-31%,170L,6.6 mL/min/kg,5-8 h,0.74,Almotriptan; bromocriptine; cabergoline; dihydroergotamine; dihydroergotamine intranasal; eletriptan; ergoloid mesylates; ergotamine; frovatriptan; methylergonovine; rizatriptan; sumatriptan; sumatriptan intranasal; zolmitriptan,Hypersensitivity; hepatic or renal impairment; Ischemic heart disease; uncontrolled hyoertention,Category B3,Not recommended,NA,,
Butenafine (Hydrochloride),Antifungal,Steroid biosynthesis,SQLE,fungal squalene epoxidase inhibitor,,,,,CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12.Cl,353.937,6.1911,1,0,4,3.24,0,-2.45,,,,-0.08,,,,0.4285,,5.772,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5824923974,,,,,,,,None,Hypersensitivity,Category C,Use with caution,NA,,
Cromolyn (sodium),"Antiallergic, Antiasthmatic",NA,,,,,,,O=C([O-])c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)[O-])cc(=O)c34)cccc2o1.[Na+].[Na+],512.334,-6.5469,11,1,8,179.37,0,1.09,,,,0.02,,,,0.06696,,28.47,,,,,,,0,2.266314145,0,0,Inactive,0,-2.68027481,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,1.735099977,0,0,Inactive,Inactive,0,-0.6584169693,,,,,,0,-28.75961186,,,,,,,0.5864127986,Oral,,,,,1.3 h,0.01,NA,Hypersensitivity,Category B1,Use with caution,NA,,
Ropinirole (hydrochloride),Antiparkinsonian,"Neuroactive ligand-receptor interaction, Dopaminergic synapse","ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",dopamine receptor agonist,,,,Ki,CCCN(CCC)CCc1cccc2c1CC(=O)N2.Cl,296.842,3.2675,2,1,7,32.34,0,0.37,,,,0.2,,,,-0.01531,,-0.3156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5921840054,Oral,,40%,7.5 l/KG,47 l/H,6 h,45-55%,None,Hypersensitivity,Category B3,Not recommended,NA,,
Prucalopride (succinate),Prokinetic,"Serotonergic synapse, Neuroactive ligand-receptor interaction",HTR4,serotonin receptor agonist,,,,Ki,COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1.O=C(O)CCC(=O)O,485.965,2.0236,7,4,9,151.42,0,,,,,-0.02,,,,,,29.32,,,,,,,0,0.9350888638,,,,0,0,,,,,,,,,,,,,,,,0,14.79270845,,,,,,0,-15.17516307,,,,,,,0.597279342,Oral,3.79ng/ml,30%,623 L,17 L/h,18-20 h,Reaches maximum plasma concentration of 3.79ng/ml with a tmax of 2.77 hours after initial administration,None,Hypersensitivity,Category B1,Not recommended,NA,,
Pitolisant (hydrochloride),Nootropic,Neuroactive ligand-receptor interaction,HRH3,histamine receptor antagonist,,,,Ki,Cl.Clc1ccc(CCCOCCCN2CCCCC2)cc1,332.315,4.587,2,0,8,12.47,0,-7.2,,,,0.19,,,,,,13.59,,,,,,,7.943282347,-93.81849103,31.6228,76.3846,Inconclusive,0,-66.55218849,0,0,Inactive,Inactive,39.81071706,-17.39072091,39.8107,59.6482,Inconclusive,39.81071706,-11.49372957,39.8107,38.4222,Inconclusive,Cytotoxic,14.12537545,30.5982577,,,,,,0,-2.64570426,,,,,,,0.6096710476,Oral,30ng/ml after oral dose of 20mg,91-96%,1100-2825 L,43.9 L/hr,10-12 h,0.9,None,Hyoersensitivity; Hepatic impairement,NA,Use with caution,NA,,
Sertaconazole (nitrate),Antifungal,Steroid biosynthesis,,sterol demethylase inhibitor,,,5.075,pIC50,Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1.O=[N+]([O-])O,500.791,6.6684,6,1,6,90.42,1,88.93,,,,-0.15,,,,-0.4284,,7.058,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6304774542,,,>99%,,,,,NA,Hypersensitivity,NA,Use with caution,NA,,
Esmolol (hydrochloride),Antiarrhythmic,"Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes",ADRB1,adrenergic receptor antagonist,,,,,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl,331.84,1.9517,5,2,9,67.79,1,-0.79,,,,-0.02,,,,0.0536,,1.827,,,,,,,6.309573445,-18.4583765,6.3096,55.6967,Inconclusive,0,-10.99280407,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-40.76514073,0,0,Inactive,Inactive,0,5.11311629,,,,,,0,-14.14222148,,,,No,,,0.6528583758,Intravenous; oral,0.05-0.3mg/kg/mm,55%,,20 L/kg/hr,Distribution half-life: 2 mins; elimination half life: 9 mins,,None,Hypersensitivity; Sinus bradyvadia; Asthma; ,Category C,Not recommended,NA,,
Sodium Picosulfate,Laxative,NA,,,,,,,O=S(=O)([O-])Oc1ccc(C(c2ccc(OS(=O)(=O)[O-])cc2)c2ccccn2)cc1.[Na+].[Na+],481.415,-4.0522,9,0,7,145.75,0,0.17,,,,-0.06,,,,,,2.289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6536195655,Oral,Cmax is attained in 7 h,,,,7.4 h,,None,Hypersensitivity; renal impairment; GI obstruction; toxic colitis,NA,NA,NA,,
Valacyclovir (hydrochloride),Antiviral,DNA synthesis/replication,,,,,,,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21.Cl,360.802,-0.3758,9,3,7,151.14,1,-3.85,,,,0.13,,,,0.01019,,-4.848,,,,,,,39.81071706,-53.01135434,39.8107,66.7301,Inconclusive,0,0.2856305278,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-0.4495417646,,,,,,0,-15.30384158,,,,,,,0.6570835258,Oral; intravenous,,13.5-17.9%,1.34 ± 0.65 L/kg for 15 ml/kg dose,255 ± 86 mL/min,2.5-3.3 h,54.5% ± 9.1%,None,Hypersensitivity,Category B3,Use with caution,NA,,
Clemastine (fumarate),Antiallergic,"Neuroactive ligand-receptor interaction, Calcium signaling pathway",HRH1,histamine receptor antagonist,,,8.5228,pIC50,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1.O=C(O)/C=C/C(=O)O,459.97,4.8162,4,2,8,87.07,2,-10.71,,,,0.18,,,,-0.1711,,27.58,,,,,,,10,-67.46410557,10,86.1768,Active,15.84893192,-85.5251403,0,0,Inactive,Inactive,4.466835922,-111.9028805,4.4668,84.5044,Active,22.38721139,-59.42625503,22.3872,53.6275,Inconclusive,Cytotoxic,11.22018454,67.30973208,10,100.279,Active,,,0,-19.10715596,0,0,Inactive,Inactive,,,0.6765636608,Oral; Intravenous,,,,The mean clearance of bremelanotide is 6.5±1.0L/hr,,,None,Asthma; hypersensitivity; nursing women,Category A,Use with caution,NA,,
Phenylephrine (hydrochloride),"Midriatic, Vasoconstrictor,","Neuroactive ligand-receptor interaction, Calcium signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D",adrenergic receptor agonist,0.86,,,EC50,CNC[C@H](O)c1cccc(O)c1.Cl,203.669,1.0668,3,3,3,52.49,1,-0.74,,,,-0.08,,,,,,28.74,,,,,,,12.58925412,-22.65280341,12.5893,35.5295,Inconclusive,0,-28.79422722,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-33.16950157,0,0,Inactive,Inactive,0,-1.81212656,,,,,,0,-13.80615341,,,,,,,0.6923726881,Oral; parenteral; Ophthalmic,,Data regarding the protein binding of phenylephrine in serum is not readily available,The volume of distribution of phenylephrine is 340L,Phenylephrine has an average clearance of 2100mL/min,Intravenous phenylephrine has an effective half life of 5 minutes and an elimination half life of 2.5 hours.,0.38,Iobenguane I 123; isocarboxazid; linezolid; phenelzine; procarbazine; selegiline transdermal; tranylcypromine,None,Category B2,Use with caution,NA,,
Allopurinol riboside,Anti-gout,"Purine metabolism, Peroxisome",,"anti-leishmanial agent, phosphorylase inhibitor",,,,,O=c1[nH]cnc2c1cnn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,268.229,-2.2689,8,4,2,133.49,4,-5.55,,,,0,,,,,,16.09,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.710329359,Oral; parenteral,"3 mcg/mL of allopurinol 
 6.5 mcg/mL of oxipurinol",Allopurinol and oxypurinol are only negligibly bound to plasma proteins,"Allopurinol and oxypurinol are both substrates for the enzyme xanthine oxidase, which is present in the cytoplasm of endothelial cells of capillaries, including sinusoids, with the highest activity demonstrated in the liver and intestinal lining. Tissue concentrations of allopurinol have not yet been reported in humans, however, it is probable that allopurinol and the metabolite oxypurinol would be measured in the highest concentrations in the abovementioned tissues. In animals, allopurinol concentrations are found to reach the highest levels in the blood, liver, intestine and heart, and lowest in the brain and lung tissues","Since allopurinol and its metabolites are mainly eliminated by the kidney, accumulation of this drug can occur in patients with renal dysfunction or failure, and the dose of allopurinol should, therefore, be reduced. With a creatinine clearance of 10 to 20 mL/min, a daily dosage of 200 mg of allopurinol is suitable. When the creatinine clearance is less than 10 mL/min, the daily dosage should not be higher than 100 mg. With severe renal impairment (creatinine clearance measured at less than 3 mL/min) a longer interval between doses may be required","The plasma half-life of allopurinol is 1-2 hours, due to its rapid renal clearance",,None,Hypersensitivity,NA,NA,NA,,
Bromocriptine (mesylate),Antiparkinsonian,"Neuroactive ligand-receptor interaction, Dopaminergic synapse, Prolactin signaling pathway,","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7",dopamine receptor agonist,,,,pKi,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O,750.713,2.6968,8,4,5,172.58,6,,,,,,,,,-0.08637,,,,,,,,,31.6227766,-10.93051803,31.6228,38.9024,Inconclusive,0,-6.078888968,0,0,Inactive,Inactive,28.18382931,-56.97996502,28.1838,116.056,Inconclusive,0,-0.1147704194,0,0,Inactive,Inactive,,,,,,,,,,,,,,,,0.9209876543,Oral,,90-96% bound to serum albumin,,,2-8 hours,0.06,Almotriptan; chloramphenicol; eletriptan; frovatriptan; glyceryl trinitrate pr; lopinavir; naratriptan; nitroglycerin IV; nitroglycerin sublingual; nitroglycerin topical; nitroglycerin transdermal; nitroglycerin translingual; posaconazole; sumatriptan; sumatriptan intranasal; zolmitriptan,Hyoersensitivity; uncontrolled hypertention; hyperprolactinemia; CAD,Category A,Not recommended,NA,,
Terbinafine hydrochloride,Antifungal,Steroid biosynthesis,SQLE,fungal squalene epoxidase inhibitor,,,,Ki,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12.Cl,327.899,5.2991,1,0,4,3.24,0,-5.95,,,,0.04,,,,,,6.375,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6774455552,Oral; Topical, 1µg/mL,"Terbinafine is >99% bound to proteins in plasma, mostly to serum albumin, high and low density lipoproteins, and alpha-1-acid glycoprotein to a lesser extent.",A single 250mg oral dose of terbinafine has a volume of distribution at steady state of 947.5L or 16.6L/kg.,A single 250mg oral dose of terbinafine has a clearance of 76L/h or 1.11L/h/kg.,"Oral terbinafine has an effective half life of approximately 36 hours. However, the terminal half life ranges from 200-400 hours as it distributes into skin and adipose tissue. 1% topical terbinafine's half life increases over the first seven days from approximately 10-40 hours.",~40%,None,Hypersensitivity; Chronic/active liver disease,Category B1,Not recommended,NA,,
Cefuroxime axetil,Antibacterial,Peptidoglycan biosynthesis,,bacterial cell wall synthesis inhibitor,,,,,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OC(C)OC(C)=O)=C(COC(N)=O)CS[C@H]12)c1ccco1,510.481,-0.1683,12,2,9,189.06,3,1.31,,,,-0.13,,,,0.1456,,17.81,,,,,,,35.48133892,-20.09463568,35.4813,65.1073,Inconclusive,0,13.50182714,0,0,Inactive,Inactive,0,8.378322507,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,1.377925043,,,,,,0,-9.963139297,,,,,,,0.6398450578,Oral; Parenteral,,50% to serum protein,,,Approximately 80 minutes following intramuscular or intravenous injection.,"37%
 52% (fed conditions)",NA,NA,Category B1,Use with caution,NA,,
GLICLAZIDE,Antidiabetic,"ABC transporters, Insulin secretion",,"ATP channel blocker, insulin secretagogue",,,6.22,pKd,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1,323.418,1.62982,4,2,3,78.51,2,,,,,,,,,0.09396,0.08068,,,,,,,,0,9.976098663,0,0,Inactive,0,-57.82743515,0,0,Inactive,Inactive,0,-24.36339043,0,0,Inactive,0,-90.60360853,0,0,Inactive,Inactive,0,-1.751943978,,,,,,0,18.02008076,,,,,,,0.6612380351,Oral,,"94%, highly bound to plasma proteins",0.43 L/kg,0.41 mL/min/kg,16.40 hours,97 %,NA,NA,Category C,Not recommended,None,,
TRICLABENDAZOLE,Anthelmintic,NA,DNMT1,microtubule inhibitor,,,,,CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1,359.665,6.0373,3,1,3,37.91,0,-0.51,,,,1.38,,,,0.1948,0.18,20.44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,3.652468653,,,,,,0,-13.93024781,,,,,,,0.3827537112,Oral,,,The apparent volume of distribution (Vd) of the sulfoxide metabolite in fed patients is about 1 L/kg.[FDA label],,"The plasma elimination half-life (t1/2) of triclabendazole, the sulfoxide and sulfone metabolites in human is about 8, 14, and 11 hours, respectively.[FDA label]",,None,Hypersensitivity,NA,No sufficient information is available,NA,,
CARBIMAZOLE,Antithyroid,Thyroid hormone synthesis,TPO,,,,,,CCOC(=O)n1ccn(C)c1=S,186.236,1.56069,5,0,1,36.16,0,1.57,,,,0.05,,,,0.0747,0.2511,5.31,,,,,,,0,-5.466777154,0,0,Inactive,0,10.58178326,0,0,Inactive,Inactive,0,-8.356233011,0,0,Inactive,0,-2.460415392,0,0,Inactive,Inactive,0,8.449704386,,,,,,0,-11.21320167,,,,,,,0.4500736703,Oral,,,,,,0 %,NA,NA,Category C,Not recommended,NA,,
MECAMYLAMINE HYDROCHLORIDE,Antihypertensive,"Neuroactive ligand-receptor interaction, Cholinergic synapse","CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB4",acetylcholine receptor antagonist,,,7,pKi; pIC50,CNC1(C)C2CCC(C2)C1(C)C,203.757,2.8424,1,1,1,12.03,3,,,,,0.56,,,,,0.1041,16.11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.4003608421,Oral,,40%,,,,99 %,None,Hypersensitivity; coronary insufficiency; glaucoma; uremia,Category C,Use with caution,NA,,
BUSPIRONE HYDROCHLORIDE,Anxiolytic,"Neuroactive ligand-receptor interaction, Serotonergic synapse, Dopaminergic synapse","DRD2, HTR1A",serotonin receptor agonist,,,7.602,pIC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,421.973,2.51,6,0,6,69.64,0,,,,,,,,,,0.1391,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.4724172518,Oral,single oral doses of 20 mg- 1 to 6 ng/mL,,"In a pharmacokinetic study assessing buspirone over the dose range of 10 to 40 mg, the volume of distribution was 5.3 L/kg.[A181027]","In a pharmacokinetic study assessing buspirone over the dose range of 10 to 40 mg, the systemic clearance was 1.7 L/h/kg.[A181027]","In a single-dose pharmacokinetic study of 14C-labeled buspirone, the average elimination half-life of unchanged buspirone following administration of single doses ranging from 10 to 40 mg was about 2 to 3 hours.[L4478]",3.90 %,Isocarboxazid; linezolid; phenelzine; procarbazine; selegiline transdermal; tranylcypromine,Hypersensitivity,Category B1,Not recommended,NA,,
RIMANTADINE HYDROCHLORIDE,Antiviral,NA,,RNA synthesis inhibitor,,,,,CC(N)C12CC3CC(CC(C3)C2)C1,215.768,2.9718,1,1,1,26.02,5,,,,,0.05,,,,,0.1024,10.22,,,,,,,35.48133892,-35.52676798,35.4813,80.1774,Inconclusive,0,10.80259426,0,0,Inactive,Inactive,0,-51.88516128,0,0,Inactive,0,-69.13201711,0,0,Inactive,Inactive,0,0.7084944396,,,,,,0,-18.83233405,,,,,,,0.5454018652,Oral,,Approximately 40% over typical plasma concentrations.,,,25 to 30 hours in young adults (22 to 44 years old). Approximately 32 hours in elderly (71 to 79 years old) and in patients with chronic liver disease. Approximately 13 to 38 hours in children (4 to 8 years old).,,None,Hypersensitivity,Category C,Not recommended,NA,,
GLIPIZIDE,Antidiabetic,"ABC transporters, Insulin secretion","ABCC4, ABCC8, KCNJ10, KCNJ11, PPARG",,,,3.8761,pIC50,Cc1ncc(nc1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,445.545,2.07812,6,3,7,130.15,0,-4.06,,,,-0.04,,,,0.03796,0.0999,5.804,,,,,,,0,-29.88856501,0,0,Inactive,0,-4.444033117,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,1.406938717,0,0,Inactive,Inactive,0,2.814606263,,,,,,0,-16.1140697,,,,,,,0.7090339795,Oral,,"Glipizide is about 98-99% bound to serum proteins, with albumin being the main plasma protein",0.16 L/kg,0.56 mL/min/kg,3.30 hours,95 %,None,Hypersensitivity; sulfa allergy; Type 1 diabetes; Diabetic ketoacidosis with or without coma,Category C,Use with caution,None,,
XYLOMETAZOLINE HYDROCHLORIDE,Vasoconstrictor,"Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",adrenergic receptor agonist,,,,pKi,Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C,280.843,3.56694,2,1,2,24.39,0,,,,,-0.09,,,,,,13.6,,,,,,,3.981071706,-68.16613722,3.9811,64.4438,Inconclusive,0,0,0,0,Inactive,Inactive,0,-1.193966799,0,0,Inactive,0,0.5716011923,0,0,Inactive,Inactive,14.12537545,21.83646525,,,,,,0,-32.38664064,,,,,,,0.7413793103,Nasal,,,,,,,Isocarboxazid; linezolid; phenelzine; selegiline transdermal; tranylcypromine,Heart diseases,Category C,No sufficient information is available,NA,,
MECLIZINE HYDROCHLORIDE,Anti-emetic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",NR1I3,constitutive androstane receptor (CAR) agonist,,,,,Clc1ccc(cc1)C(N1CCN(CC1)Cc1cccc(C)c1)c1ccccc1,463.88,6.39922,2,0,5,6.48,1,,,,,1.33,,,,,,12.5,,,,,,,6.309573445,-11.01066177,0,0,Inactive,0,6.025062211,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-4.072000475,,,,,,0,-10.75000337,,,,,,,0.1115153432,Oral,,,The volume of distribution of meclizine in humans has not been fully studied. It is proposed that meclizine may be excreted into breast milk.[L6760],There is limited data on the clearance of meclizine.,Meclizine has a plasma elimination half-life of about 5-6 hours in humans.[L6772],,NA,Hypersensitivity,Category B,Use with caution,NA,,
CYCLOSERINE (D),Antibacterial (tuberculostatic),"Peptidoglycan biosynthesis, D-Alanine metabolism",GRIN1,bacterial cell wall synthesis inhibitor,,,,,N[C@@H]1CONC1=O,102.093,-1.6249,3,2,0,64.35,1,-2.21,,,,0.17,,,,1.427,,23.75,,,,,,,0,-18.79928126,0,0,Inactive,0,-4.58351177,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.616934082,0,0,Inactive,Inactive,0,-4.81934027,,,,,,0,-18.34068652,,,,,,,0.3545723212,Oral,,,,,"Half-life in patients with normal renal function is 10 hours, and is prolonged in patients with impaired renal function.",80 %,NA,Hypersensitivity; Severe renal dysfunction; seizures,Category C,Use with caution,NA,,
CARTEOLOL HYDROCHLORIDE,"Antiglaucoma, Antiarrhythmic, Antihypertensive","Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, cAMP signaling pathway","ADRB1, ADRB2, ADRB3",adrenergic receptor antagonist,,,,pKi,OC(COc1cccc2NC(=O)CCc12)CNC(C)(C)C,328.84,2.1209,4,3,5,70.59,1,,,,,,,,,,0.1646,,,,,,,,0,-10.74187383,0,0,Inactive,0,-31.56538022,0,0,Inactive,Inactive,0,3.405700329,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0.4256420041,,,,,,0,-23.93488554,,,,,,,0.3590772317,Oral; Ophthalmic,,,,10.10 mL/min/kg,4.70 hours,88 %,NA,"Asthma, uncompensated CHF, any beta-blocker side effects, hypersensitivity, severe COPD, 2°/3° AV block, cardiogenic shock",NA,Not recommended,None,,
DICYCLOMINE HYDROCHLORIDE,Antispasmodic,"Calcium signaling pathway, Neuroactive ligand-receptor interaction, cholinergic synapse, cAMP signaling pathway",,,,,,pKi,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1,345.955,4.824,3,0,7,29.54,0,,,,,,,,,,0.1568,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.3971915747,Oral; parenteral,,,The volume of distribution for a 20mg oral dose is 3.65L/kg.[L7967],Data regarding the clearance of dicyclomine is not readily available.[L7967],"The mean plasma elimination half life is approximately 1.8 hours.[A182525,L7967]",,None,Hypersensitivity to dicyclomine or any anticholinergic drugs; Closed-angle glaucoma; Myasthenia gravis; Hemorrhage with cardiovascular instability; Paralytic ileus; Breast-feeding; Intestinal atony of elderly/debilitated patients; Toxic megacolon; GI obstruction; Obstructive uropathy; Severe ulcerative colitis; Reflux esophagitis,Category B1,Not recommended,None,,
DIMENHYDRINATE,"Anti-emetic, Antivertigo","Calcium signaling pathway, Neuroactive ligand-receptor interaction",HRH1,histamine receptor antagonist,,,4.0757,Pic50,CN(C)CCOC(c1ccccc1)c1ccccc1.Clc1[nH]c2c(n1)n(C)c(=O)n(C)c2=O,469.973,2.9679,7,1,6,85.15,0,-1.08,,,,0,,,,1.153,,16.23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.4215800467,Oral; parenteral,"72.6 ng/mL (50 mg oral film coated tablet)
",98 to 99%.,,,1 to 4 hours,,None,Hypersensitivity; Asthma; neonates; nursing women,Category A,Use with caution,NA,,
ACYCLOVIR,Antiviral,DNA synthesis/replication,PNP,DNA polymerase inhibitor,,,,,OCCOCn1cnc2c(=O)[nH]c(N)nc12,225.208,-1.3318,7,3,4,119.05,0,8.75,,,,0.04,,,,0.1444,0.1075,6.729,,,,,,,0,0,0,0,Inactive,0,-7.013668247,0,0,Inactive,Inactive,0,6.837535791,0,0,Inactive,0,-23.22050268,0,0,Inactive,Inactive,0,3.824972343,,,,,,0,6.759000897,,,,,,,0.4829516558,Oral; Topical; Buccal; Parenteral,,Acyclovir is 9-33% protein bound in plasma.,0.71 L/kg,4.70 mL/min/kg,2.50 hours,22.50 %,None,Hypersensitivity,Category B3,Use with caution,NA,,
TETRAHYDROZOLINE HYDROCHLORIDE,Vasoconstrictor,"Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction",GNA15,adrenergic receptor agonist,,,4.5243,pIC50,C1CN=C(N1)C1CCCc2ccccc12,236.746,2.53,2,1,1,24.39,1,,,,,-0.05,,,,,0.1519,17.25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5352342221,Nasal,,,,,,,None,Hypersensitivity,Category C,No sufficient information is available,NA,,
PROPANTHELINE BROMIDE,Antispasmodic,"Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Gastric acid secretion","CHRM1, CHRM2, CHRM3, CHRM4",acetylcholine receptor antagonist,,,,pKi,O=C(OCC[N+](C)(C(C)C)C(C)C)C1c2ccccc2Oc2ccccc12,448.401,1.7348,3,0,6,35.53,0,,,,,-0.02,,,,,0.1356,10.7,,,,,,,0,-18.54992209,0,0,Inactive,0,5.593244844,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,10.09246769,0,0,Inactive,Inactive,0,-2.874992878,,,,,,0,-11.76271043,,,,,,,0.5453798917,Oral; parenteral,,,,,,,None,"Hypersensitivity; Closed-angle glaucoma, myasthenia gravis, hemorrhage w/ cardiovascular instability, paralytic ileus, intestinal atony of elderly/debilitated pt, obstructive uropathy, toxic megacolon, GI obstruction",Category B2,Use with caution,None,,
ETHIONAMIDE,Antibacterial (tuberculostatic),NA,,mycolic synthesis inhibitor,,,,,CCc1nccc(c1)C(=S)N,166.249,1.2782,2,1,2,38.91,0,-1.84,,,,-0.13,,,,0.1212,0.1784,18.18,,,,,,,0,3.664284582,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-12.94469923,0,0,Inactive,0,-8.556702746,0,0,Inactive,Inactive,0,-4.723959701,,,,,,0,-16.97779043,,,,,,,0.6020061495,Oral,,Approximately 30% bound to proteins.,* 93.5 L [healthy volunteers],,2 to 3 hours,80 %,None,Hypersensititvity; severe hepatic dysfunction,Category C,Use with caution,NA,,
GLYBURIDE,Antidiabetic,"ABC transporters, Insulin secretion","ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1","ATP channel blocker, insulin secretagogue, sulfonylurea",,,6.6575,pIC50,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,494.013,3.6417,5,3,8,113.6,0,-1.61,,,,-0.07,,,,0.2282,,13.62,,,,,,,0,-36.89466252,0,0,Inactive,0,8.352390454,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-2.174900403,,,,,,0,-15.87166242,,,,,,,0.6092510152,Oral,"211-315ng/mL- elderly
144-302ng/mL- younger patients ",Glyburide is 99.9% bound to protein in plasma with >98% accounted for by binding to serum albumin.,0.08 L/kg,0.82 mL/min/kg,2.20 hours,82 %,Bosentan,Hypersensitivity; sulfa allergy; Type 1 diabetes; Diabetic ketoacidosis with or without coma,NA,Use with caution,None,,
CHLORZOXAZONE,Skeletal muscle relaxant,NA,"KCNMA1, KCNN4",bacterial 30S ribosomal subunit inhibitor,,,4.52,pEC50,Clc1ccc2oc(=O)[nH]c2c1,169.567,1.7745,2,1,0,46,0,-2.41,,,,-0.11,,,,0.06344,0.18,25.61,,,,,,,0,1.888942275,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,1.673643933,0,0,Inactive,0,7.506901628,0,0,Inactive,Inactive,0,3.311931149,,,,,,0,-8.490194639,,,,,,,0.6248568969,Oral,,,,,,,None,Hypersensititvity,NA,NA,NA,,
ALLOPURINOL,Anti-gout,"Purine metabolism, Peroxisome",XDH,xanthine oxidase inhibitor,,,5.699,pIC50,O=c1[nH]cnc2[nH]ncc12,136.114,-0.3538,3,2,0,74.43,0,-27.22,,,,0.35,,,,0.1167,0.02121,15.51,,,,,,,0,-390.9998703,0,0,Inactive,14.12537545,-258.1436537,0,0,Inactive,Inactive,0,-416.4756609,0,0,Inactive,0,-250.3642621,0,0,Inactive,Inactive,0,-1.430080843,,,,,,0,-10.15203611,,,,,,,0.6690532191,Oral; parenteral,3 mcg/mL (300 mg oral dose),Allopurinol and oxypurinol are only negligibly bound to plasma proteins,0.58 L/kg,11 mL/min/kg,0.80 hours,53 %,None,Hypersensitivity,Category B2,Not recommended,None,,
PHENYLEPHRINE HYDROCHLORIDE,"Midriatic, Vasoconstrictor","Calcium signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D",adrenergic receptor agonist,,,5.9,pIC50,CNC[C@H](O)c1cccc(O)c1,203.669,1.0668,3,3,3,52.49,1,,,,,-0.07,,,,,0.03283,17.14,,,,,,,12.58925412,-22.65280341,12.5893,35.5295,Inconclusive,0,-28.79422722,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-33.16950157,0,0,Inactive,Inactive,0,-1.81212656,,,,,,0,-13.80615341,,,,,,,0.7757726676,Oral; parenteral; Ophthalmic,,,"The volume of distribution of phenylephrine is 340L.[L9416,L9410]","Phenylephrine has an average clearance of 2100mL/min.[L9416,L9410]","Intravenous phenylephrine has an effective half life of 5 minutes and an elimination half life of 2.5 hours.[A187379,L9416,L9410]",35 %,Iobenguane I 123; isocarboxazid; linezolid; phenelzine; procarbazine; selegiline transdermal; tranylcypromine,None,Category B2,Use with caution,NA,,
ETHAMBUTOL HYDROCHLORIDE,Antibacterial (tuberculostatic),NA,ABCC4,bacterial cell wall synthesis inhibitor,,,3.876,pIC50,CC[C@@H](CO)NCCN[C@@H](CC)CO,277.236,0.551,4,4,9,64.52,2,,,,,-0.14,,,,,,4.24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8345460297,Oral,25 mg/kg oral dose of ethambutol- 2-5 µg/mL,Ethambutol is 20-30% bound to protein in plasma,1.70 L/kg,10 mL/min/kg,3.10 hours,77 %,None,Hypersensitivity; Known optic neuritis,Category A,Recommended,NA,,
PYRIMETHAMINE,Antimalarial,"Pyrimidine metabolism, Folate biosynthesis","DHFR, SLC47A1",dihydrofolate reductase inhibitor,,,,Ki,CCc1nc(N)nc(N)c1c1ccc(Cl)cc1,248.717,2.5238,4,2,2,77.82,0,57.63,,,,9.02,,,,0.7421,0.2473,15.45,,,,,,,39.81071706,-45.50275512,39.8107,45.106,Inconclusive,39.81071706,-30.35835158,39.8107,51.4894,Inconclusive,Cytotoxic,39.81071706,-22.9004696,39.8107,78.5461,Inconclusive,39.81071706,-22.31717971,39.8107,88.4059,Inconclusive,Cytotoxic,11.22018454,31.4146497,,,,,,6.309573445,-86.57631335,,,,,,,0.09896852835,Oral,,87%,0.43 L/kg,0.05 mL/min/kg,140 hours,90 %,Eliglustat,Hypersensitivity; Megaloblastic or folate-deficiency anemia,Category B3,Not recommended,na,,
PRAZIQUANTEL,Anthelmintic ,NA,ABCC4,,,,3.8761,pIC50,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1,312.413,2.5349,2,0,1,40.62,1,,,,,,,,,0.2207,,,,,,,,,0,-121.9808706,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-95.39783475,0,0,Inactive,0,-9.730679791,0,0,Inactive,Inactive,0,-0.8732270376,,,,,,0,-23.06392689,,,,,,,0.4339506173,Oral,,80 to 85%,,,0.8-1.5 hours (in serum),7 %,Bosentan; carbamazepine; dabrafenib; dexamethasone; efavirenz; enzalutamide; eslicarbazepine acetate; etravirine; fosphenytoin; mitotane; nafcillin; nevirapine; oxcarbazepine; pentobarbital; phenobarbital; phenytoin; primidone; rifabutin; rifampin; rifapentine,Hypersensitivity; Intraocular cysticercosis,Category B1,Not recommended,None,,
GUAIFENESIN,"Antitussive, Expectorant",NA,ABCB11,,,,3,pIC50,OCC(O)COc1ccccc1OC,198.218,0.4272,4,2,5,58.92,1,,,,,,,,,0.07395,0.2008,,,,,,,,0,-163.6664449,0,0,Inactive,0,2.68545671,0,0,Inactive,Inactive,0,-73.80624427,0,0,Inactive,0,2.548150528,0,0,Inactive,Inactive,0,-2.35940406,,,,,,0,-40.28008734,,,,,,,0.4448790817,Oral,,,The geometric mean apparent volume of distribution of guaifenesin determined in healthy adult subjects is 116L (CV=45.7%) [F4525].,The mean clearance recorded for guaifenesin is about 94.8 L/hr (CV=51.4%) [F4525].,"The half-life in plasma observed for guaifenesin is approximately one hour [A177676, L6079, L6100, F4522, F4525].",,None,Hyersensitivity,Category A,Not recommended,None,,
SULFAMETHIZOLE,Antibacterial,Folate biosynthesis,CYP3A4,,,,3.0777,pIC50,Nc1ccc(cc1)S(=O)(=O)Nc1nnc(C)s1,270.339,1.22952,6,2,3,97.97,0,13.56,,,,0.11,,,,0.01199,0.1221,14.03,,,,,,,0,-69.33899868,0,0,Inactive,0,1.808839996,0,0,Inactive,Inactive,0,-101.6746949,0,0,Inactive,0,-1.252950462,0,0,Inactive,Inactive,0,10.36194773,,,,,,0,-5.116155161,,,,,,,0.4983453403,Oral,,98-99%,,,3-8 hours,,NA,NA,Category C,NA,NA,,
ALLANTOIN,"Anti-inflammatory,",NA,,,,,,,NC(=O)NC1NC(=O)NC1=O,158.117,-2.1798,3,4,1,113.32,1,,,,,,,,,0.03873,0.1646,,,,,,,,0,-153.0303877,0,0,Inactive,0,-1.820218614,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,9.772898339,,,,,,0,-10.89733528,,,,,,,0.5471312084,,,,,123 cc/min,1 to 2.5 h,,NA,NA,NA,NA,NA,,
BETHANECHOL CHLORIDE,Prokinetic,"Neuroactive ligand-receptor interaction, Cholinergic synapse, Gastric acid secretion","CHRM1, CHRM2, CHRM3, CHRM4",acetylcholine receptor agonist,,,,pKi,NC(=O)OC(C)C[N+](C)(C)C,196.678,-2.8196,2,1,3,52.32,1,,,,,,,,,,0.07337,,,,,,,,0,-4.509911624,0,0,Inactive,0,-7.708451783,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-10.02456742,0,0,Inactive,Inactive,0,-0.8736276185,,,,,,0,-21.82276324,,,,,,,0.7311935807,Oral; Subcutaneous,,,,,,,None,Hypersensitivity; hyperthyroidism; peptic ulcer; asthma; bradycardia; hypotension; AV conduction defects; CAD vasomotor instability; vagotonia; epilepsy; Parkinsonism; GI of GU obstruction; weak bladder wall; recent urinary bladder surgery; GI resection or anastomosis; spastic GI disturbances; HTN; obstructive pulmonary disease,Category B2,Use with caution,NA,,
PAPAVERINE HYDROCHLORIDE,"Antispasmodic, Smooth muscle relaxant, Vasodilator","Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway","PDE10A, PDE4B, PDE5A",phosphodiesterase inhibitor,,,7.7695,pIC50,COc1ccc(cc1OC)Cc1nccc2cc(OC)c(OC)cc12,375.852,4.2818,5,0,6,49.81,0,,,,,-0.24,,,,,0.03666,17.4,,,,,,,6.309573445,-165.60092,,,,7.943282347,-57.35432358,,,,,,,,,,,,,,,,0,-8.101621942,,,,,,0,-30.76905128,,,,,,,0.8955617247,,,~90%,1 L/kg,11 mL/min/kg,1.80 hours,28 %,None,Hypersensitivity; Complete AV block,Category B3,Use with caution,None,,
OXYMETAZOLINE HYDROCHLORIDE,Vasoconstrictor,"Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",adrenergic receptor agonist,,,,pKi,Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C,296.842,3.27254,3,2,2,44.62,0,,,,,0.07,,,,,0.2228,24.54,,,,,,,0,-11.59692265,0,0,Inactive,0,4.77084277,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.0924169322,0,0,Inactive,Inactive,0,-2.828628313,,,,,,0,-2.257233181,,,,,,,0.3077977209,,60.5 ± 53.9 pg/mL,56.7-57.5%,,,,11 %,None,None,NA,Use with caution,None,,
PROBUCOL,Antihyperlipidemic,NA,"ABCA1, ABCB11, CES1",atherogenesis inhibitor,,,,,Oc1c(cc(cc1C(C)(C)C)SC(C)(C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)C(C)(C)C,516.857,9.9083,4,2,4,40.46,0,2.84,,,,0.59,,,,0.2869,,26.51,,,,,,,7.079457844,-89.88755971,7.0795,36.9486,Inconclusive,0,4.879739045,0,0,Inactive,Inactive,0,-120.256949,0,0,Inactive,0,7.13969797,0,0,Inactive,Inactive,0,7.335153905,,,,,,0,-18.44881848,,,,,,,0.3445969443,Oral,,,,,"Ranges from 12 h - 500 h, the longest half-life probably being in adipose tissue.",5 %,NA,NA,Category B1,NA,NA,,
CHLORPROPAMIDE,"Antidiabetic, Hypoglycemic","ABC transporters, Insulin secretion","ABCC8, ABCC3, KCNJ10",ATP channel blocker,,,3.8761,pIC50,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,276.745,1.7379,3,2,4,75.27,0,4.33,,,,0.09,,,,0.09227,0.2087,13.38,,,,,,,0,-45.49609625,0,0,Inactive,0,12.11952663,0,0,Inactive,Inactive,0,-73.05797368,0,0,Inactive,0,0.2193005497,0,0,Inactive,Inactive,0,0.4868284397,,,,,,0,-24.50570053,,,,,,,0.4175027133,Oral,Peak plasma concentrations occur within 2-4 h,Highly bound to plasma,0.19 L/kg,0.05 mL/min/kg,46 hours,95 %,Dronabinol,"Type I diabetes; Diabetes ketoacidosis; Hypersensitivity, sulfa allergy; Severe renal impairment",Category C,Use with caution,None,,
PYRAZINAMIDE,Antibacterial (tuberculostatic),NA,FASN,fatty acid synthase inhibitor,,,,,NC(=O)c1cnccn1,123.115,-0.4245,3,1,1,68.87,0,44.3,,,,0,,,,0.01701,0.1788,14.28,,,,,,,0,-30.78405555,0,0,Inactive,0,9.294300246,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,10.61496308,0,0,Inactive,Inactive,0,-3.083092535,,,,,,0,-10.19210349,,,,,,,0.4386448283,Oral,,~10%,,,9-10 hours (normal conditions),90 %,None,Hepatic damage; acute gout; hypersensitivity,Category B2,Use with caution,NA,,
BENOXINATE HYDROCHLORIDE,Anesthetic (topical),Dopaminergic synapse,SCN1A,,,,5.54,pIC50,CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC,344.883,3.3681,5,1,10,64.79,0,,,,,,,,,,0.147,,,,,,,,14.12537545,-64.71148692,0,0,Inactive,0,0.8760637702,0,0,Inactive,Inactive,39.81071706,-13.03997395,39.8107,46.9747,Inconclusive,35.48133892,-10.96066512,35.4813,35.3339,Inconclusive,Cytotoxic,0,4.143924367,,,,,,0,-33.54502775,,,,,,,0.4403209629,,,,,,,,None,Hypersensitivity,NA,NA,NA,,
PROBENECID,"Anti-gout, Uricosuric",NA,"PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1",uricosuric blocker,,,5.2007,pIC50,CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(=O)O,285.365,2.1955,3,1,7,74.68,0,1.35,,,,0.08,,,,0.2093,,15.12,,,,,,,0,-42.62226298,0,0,Inactive,0,2.200630514,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,7.699700188,0,0,Inactive,Inactive,0,0.9786742257,,,,,,0,-35.35218372,,,,,,,0.4777739026,Oral,,75-95%,0.13 L/kg,0.25 mL/min/kg,5.90 hours,99 %,None,"Uric acid kidney stones, acute gouty arthritis; Hypersensitivity; Blood dyscrasias",Category B2,Use with caution,NA,,
TOLBUTAMIDE,"Antidiabetic, Hypoglycemic","ABC transporters, Insulin secretion","ABCC8, ABCC4, KCNJ1, KCNJ11, KCNJ8",ATP channel blocker,,,3.8761,pIC50,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,270.354,1.78302,3,2,5,75.27,0,3.6,,,,0.19,,,,-0.01112,,21.67,,,,,,,0,-1.606396107,0,0,Inactive,0,2.953090091,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-3.500377777,0,0,Inactive,Inactive,0,-2.976245871,,,,,,0,-14.98582329,,,,,,,0.5416696148,Oral,,95%,0.12 L/kg,0.21 mL/min/kg,7 hours,85 %,None,"Hypersensitivity, sulfa allergy; Type I diabetes, diabetic ketoacidosis",Category C,Use with caution,None,,
NAPHAZOLINE HYDROCHLORIDE,Vasoconstrictor,Neuroactive ligand-receptor interaction,"ADRA1A, ADRA2A, ADRA2B",adrenergic receptor agonist,,,11.9586,pIC50,C1CN=C(N1)Cc1cccc2ccccc12,246.741,2.8058,2,1,2,24.39,0,,,,,0.52,,,,,0.002061,12.64,,,,,,,0,-10.96023277,0,0,Inactive,0,3.477288401,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-3.682046748,,,,,,0,-1.014273075,,,,,,,0.5467946865,Nasal,,,"Distribution data for naphazoline are scarce but imidazoline compounds are distributed throughout the body, and can cross the blood-brain barrier[T530].",,Half life has not been determined but effects last for 4 to 8 hours.,,None,"Heart disease (incr BP, HR, palpitations); Narrow angle glaucoma",NA,,None,,
TOLAZAMIDE,"Antidiabetic, Hypoglycemic","ABC transporters, Insulin secretion","ABCC8, KCNJ1, KCNJ10, KCNJ11",ATP channel blocker,,,,,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1,311.407,1.77392,4,2,3,78.51,0,8.18,,,,-0.15,,,,0.0131,0.157,32.71,,,,,,,0,-21.76094511,0,0,Inactive,0,8.29626065,0,0,Inactive,Inactive,0,2.448159297,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-2.03377317,,,,,,0,-21.41046166,,,,,,,0.5943998054,Oral,,,,,7 h,,None,Hypersensitivity; sulfa allergy; diabetic ketoacidosis; Type 1 diabetes,Category C,Not recommended,NA,,
NALIDIXIC ACID,Antibacterial,DNA synthesis/replication,,bacterial DNA gyrase inhibitor,,,,,CCn1cc(C(=O)O)c(=O)c2ccc(C)nc12,232.239,1.42302,4,1,2,72.19,0,-0.44,,,,0.12,,,,,0.03233,12.92,,,,,,,0,-5.277969596,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-9.380491449,,,,,,0,-32.77548898,,,,,,,0.6268880154,Oral ,,93%,,,"1.1 to 2.5 hours in healthy adult patients, and up to 21 hours in patients with impaired renal function.",96 %,NA,NA,Category A,Use with caution,NA,,
CLOFIBRATE,Antihyperlipidemic,"PPAR signaling pathway, Adipocytokine signaling pathway","LPL, PPARA",PPAR receptor agonist,,,4.25,pIC50,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,242.702,3.0605,3,0,4,35.53,0,,,,,,,,,0.08504,0.007924,,,,,,,,0,-42.73835177,0,0,Inactive,0,1.45023801,0,0,Inactive,Inactive,0,-5.232052235,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,9.989019192,,,,,,0,-14.01831037,,,,,,,0.7680207289,Slow,,95-97%,,,18-22 h,95 %,NA,NA,Category B1,NA,NA,,
NEOSTIGMINE BROMIDE,Parasympathomimetic,"Glycerophospholipid metabolism, Cholinergic synapse",ACHE,acetylcholinesterase inhibitor,,,10.3665,pIC50,O=C(Oc1cccc(c1)[N+](C)(C)C)N(C)C,303.2,-1.0523,2,0,2,29.54,0,,,,,-0.14,,,,,0.1096,12.59,,,,,,,0,-24.4913318,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,1.779249603,0,0,Inactive,Inactive,0,10.70682813,,,,,,0,-1.074971516,,,,,,,0.7186772275,Oral,,,0.74 L/kg,9.20 mL/min/kg,1.30 hours,2 %,None,Hypersensitivity,Category B2,Use with caution,None,,
METHOCARBAMOL,Skeletal muscle relaxant,NA,CA1,muscle relaxant,,,7.6,pKi,COc1ccccc1OCC(O)COC(=O)N,241.243,0.5302,5,2,6,91.01,1,1.12,,,,-0.31,,,,0.09817,,10.07,,,,,,,0,-97.80945854,0,0,Inactive,0,-7.605414599,0,0,Inactive,Inactive,0,-6.760039393,0,0,Inactive,0,-14.84166346,0,0,Inactive,Inactive,0,1.871579725,,,,,,0,-23.49119365,,,,,,,0.7217427285,,,Methocarbamol is 46-50% protein bound in healthy patients and 47.3-48.9% protein bound in hemodialysis patients,"Volume of distribution data in humans is scarce. In horses, the volume of distribution is 515-942mL/kg at steady state or 724-1130mL/kg.[A178426]",0.2-0.8L/h/kg.[L6268],The elimination half life is 1.14 hours in healthy subjects and 1.24 hours in subjects with renal insufficiency.[A636] Older studies report half lives of 1.6-2.15 hours.[A178366],,None,Renal impairement,Category B3,Use with caution,None,,
ACETAZOLAMIDE,Antiglaucoma,Proximal tubule bicarbonate reclamation,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",carbonic anhydrase inhibitor,,,8.2365,pIC50,CC(=O)Nc1nnc(s1)S(=O)(=O)N,222.251,-0.8561,6,2,2,115.04,0,-4.52,,,,-0.12,,,,0.04502,0.1016,9.824,,,,,,,0,-80.91885086,0,0,Inactive,0,-7.430385095,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.3515920448,0,0,Inactive,Inactive,0,1.814488279,,,,,,0,-20.63394837,,,,,,,0.7478637341,,,98%,0.37 L/kg,0.65 mL/min/kg,13 hours,99 %,None,Hypokalemia; Hyponatremia; Hyperchloremic acidosis; Hypersensitivity to acetazolamide or sulfa; Liver disease,Category B3,Use with caution,None,,
SULFADIAZINE,Antibacterial,Folate biosynthesis,"CA1, CA2, CA6",,,,4.5817,pIC50,Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1,250.283,0.8596,5,2,3,97.97,0,-3.32,,,,-0.11,,,,-0.0006413,,15.43,,,,,,,0,2.174276948,0,0,Inactive,0,-3.885093,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-7.111555396,0,0,Inactive,Inactive,0,-13.92697388,,,,,,0,-10.30040041,,,,,,,0.7982198283,,,,0.29 L/kg,0.55 mL/min/kg,7 hours,90 %,None,Should not be used for group A beta-hemolytic strep infections,Category C,Use with caution,NA,,
PHENTOLAMINE HYDROCHLORIDE,Vasodilator,"Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C",adrenergic receptor antagonist,,,8.9586,pIC50,Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1,317.82,3.26222,4,2,4,47.86,0,,,,,0.13,,,,,0.06841,14.21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5529944785,,,,,42 mL/min/kg,2.50 hours,,None,Hypersensitivity; MI or other CAD,Category B1,Not recommended,NA,,
DOXYLAMINE SUCCINATE,Anti-allergic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",HRH1,histamine receptor antagonist,,,,,CN(C)CCOC(C)(c1ccccc1)c1ccccn1.OC(=O)CCC(=O)O,388.464,2.8591,5,2,9,99.96,1,3.91,,,,-0.02,,,,-0.01157,,2.832,,,,,,,4.466835922,-51.95276167,4.4668,40.9754,Inconclusive,0,1.688250662,0,0,Inactive,Inactive,0,-5.676281589,0,0,Inactive,0,5.992165961,0,0,Inactive,Inactive,0,-0.7168042477,,,,,,0,-32.36344052,,,,,,,0.6377924624,Oral,,,,,10 hours,,None,Hypersensitivity,Category A,Not recommended,NA,,
MEPENZOLATE BROMIDE,"Antispasmodic, Anti-ulcerative","Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Gastric acid secretion",CHRM3,acetylcholine receptor antagonist,,,,pKi,O=C(OC1CCC[N+](C)(C)C1)C(O)(c1ccccc1)c1ccccc1,420.347,-0.2915,3,1,4,46.53,1,,,,,,,,,,0.1869,,,,,,,,0,-9.325692207,0,0,Inactive,0,-3.867056641,0,0,Inactive,Inactive,0,-29.44461974,0,0,Inactive,0,9.452990098,0,0,Inactive,Inactive,0,1.113614768,,,,,,0,1.941499028,,,,,,,0.2848545637,Oral,,,,,,,NA,NA,NA,Use with caution,None,,
Gefitinib (ZD1839),Antineoplastic,"MAPK signaling pathway, ErbB signaling pathway,",EGFR,EGFR inhibitor,,,10,pIC50,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,446.91,4.2756,7,1,8,68.74,0,18.82,,,,9.07,,,,0.2901,0.178,19.63,,,,,,,12.58925412,-62.77745603,12.5893,99.3085,Active,39.81071706,-30.9409406,39.8107,66.8293,Inconclusive,Cytotoxic,39.81071706,-24.25680411,39.8107,83.1981,Inconclusive,39.81071706,-13.62499036,39.8107,46.7322,Inconclusive,Cytotoxic,0,-10.88521906,,,,,,11.22018454,-120.9162432,,,,,,,0.2314783236,Oral,,90% primarily to serum albumin and alpha 1-acid glycoproteins (independent of drug concentrations).,23 L/kg,12 mL/min/kg,34 hours,60 %,None,None,Category C,Not recommended,None,,
Rucaparib (AG-014699 or PF-01367338) phosphate,Antineoplastic,"Apoptosis, Necroptosis, Base excision repair","PARP1, PARP2",PARP inhibitor,,,9.301,pIC50,CNCc1ccc(cc1)c1[nH]c2cc(F)cc3C(=O)NCCc1c23.OP(=O)(O)O,421.365,2.0507,3,6,3,134.68,0,4.71,,,,1.02,,,,,,93.3,,,,,,,31.6227766,-24.74618247,,,,0,12.01377064,,,,,,,,,,,,,,,,0,20.55052547,,,,,,0,-12.29281642,,,,,,,0.275922578,Oral,1940 ng/mL,"In vitro, the protein binding of rucaparib was 70% in human plasma at therapeutic concentrations. Rucaparib preferentially distributed to red blood cells with a blood-to-plasma concentration ratio of 1.83","Following a single intravenous dose of 12mg to 40mg rucaparib, the steady-state volume of distribution was 113L to 262L [FDA Label].","Following continuous 600mg rucaparib administration orally twice daily, the apparent clearance ranges from 15.3 to 79.2 L/hour. The clearance ranged from 13.9 to 18.4 L/hour, following a single intravenous dose of rucaparib 12 mg to 40 mg [FDA Label].","Following a single oral dose of 600mg rucaparib, the mean terminal half life (t1/2) was 17-19 hours [FDA Label].",36%; range from 30% to 45%.,Finerenone; isavuconazonium sulfate; lonafarnib; voclosporin,None,NA,Not recommended,NA,,
ETC-1002,Antidyslipidemia,Citrate cycle (TCA cycle),,,,,5.69,pKi,OC(CCCCCC(C)(C)C(=O)O)CCCCCC(C)(C)C(=O)O,344.492,4.4699,3,3,14,94.83,0,-6.33,,,,0.09,,,,,0.1415,19.18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5862585853,Oral,,The plasma protein binding of bempedoic acid and its metabolites is about 99%,The apparent volume of distribution of bempedoic acid is about 18L.[L12144],The clearance (CL/F) of bempedoic acid at steady state was estimated at 11.2 mL/min during clinical trials.[L12144],The half-life of bempedoic acid ranges between 15 and 24 hours.[A191877] Prescribing information indicates a clearance of 21 hours +/- 11 hours.[L12144],,NA,NA,NA,Not recommended,NA,,
Nifurtimox,Antiprotozoal,NA,HSPD1,DNA inhibitor,,,3.602,pIC50,CC1CS(=O)(=O)CCN1/N=C/c1ccc([N+](=O)[O-])o1,287.297,0.6406,7,0,3,106.02,1,,,,,,,,,0.8408,0.1929,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.180892678,Oral,425-568 μg/L- 20 mg single dose,The plasma protein binding of nifurtimox is approximately 42%.[L15361] It is primarily bound to albumin.[A216931],"Nifurtimox crosses the blood-brain barrier and the placenta.[A216931,L15361]",One pharmacokinetic study of nifurtimox revealed a clearance of 193.4 l∙h-1. In patients without renal failure| clearance was 99.7 l∙h-1.[A217936],The elimination half-life of nifurtimox ranges from 2.4–3.6 hours.[L15361] A pharmacokinetic study of healthy volunteers and patients with renal failure revealed respective mean half-lives of 2.95 h and 3.95 h.[A217936],,None,Hypersensitivity; alcohol consuption during treatment,NA,Use with caution,NA,,
Rimegepant,Antimigraine,Neuroactive ligand-receptor interaction,CALCA,calcitonin antagonist,,,10.56,pKi,N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F,534.567,4.49,7,2,3,119.13,3,2.52,,,,0.23,,,,,0.2662,37.92,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,6.914579925,,,,,,0,-22.05933578,,,,,,,0.3007147727,Oral,,Rimegepant is approximately 96% plasma protein-bound.[L11971] The specific proteins to which rimegepant binds have not been elucidated.,"At steady state, the volume of distribution is approximately 120 L.[L11971]",,The elimination half-life in healthy subjects is approximately 11 hours.[L11971],0.64,None,Hypersensitivity,NA,Not recommended,None,,
Moxonidine,Antihypertensive,"cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction","ADRA2A, ADRA2B, ADRA2C",imidazoline receptor agonist,,,,,COc1nc(C)nc(Cl)c1NC1=NCCN1,241.682,0.81812,6,2,2,71.43,0,,,,,0.05,,,,0.9675,0.157,19.01,,,,,,,0,-1.972047955,0,0,Inactive,0,-4.571446414,0,0,Inactive,Inactive,0,1.899039839,0,0,Inactive,0,2.379901489,0,0,Inactive,Inactive,0,0.0607491661,,,,,,0,-28.34341794,,,,,,,0.3023549532,Oral,,About 10% of moxonidine is bound to plasma proteins. [FDA label],1.80 L/kg,11 mL/min/kg,2.20 hours,88 %,NA,NA,Category B3,Use with caution,NA,,
Lubiprostone,"Peristaltic accelerator, Softener,",Mineral absorption,CLCN2,chloride channel activator,,,,,CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,390.467,4.1525,4,2,14,91.67,3,15.74,,,,0.06,,,,,,4.135,,,,,,,0.316227766,-137.3361044,0.3162,33.381,Inconclusive,0,-0.5006994453,0,0,Inactive,Inactive,0,-18.30548514,0,0,Inactive,0,1.110682404,0,0,Inactive,Inactive,0,-6.62631798,,,,,,0,-41.34699071,,,,,,,0.3353151279,Oral,,94%,,,0.9 to 1.4 hours,,None,Hypersensitivity,NA,use with caution,None,,
Capmatinib,Antineoplastic,"Ras signaling pathway, PI3K-Akt signaling pathway",,,,,,,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,412.428,3.429,6,1,4,85.07,0,1.59,,,,1.09,,,,,,8.178,,,,,,,39.81071706,-9.18247318,,,,0,0,,,,,,,,,,,,,,,,0,5.29026748,,,,,,0,-27.65320488,,,,,,,0.3414023231,Oral,,Plasma protein binding is approximately 96% and is independent of drug serum concentration.[L13347],The apparent volume of distribution at steady-state is 164 L.[L13347],The mean apparent clearance of capmatinib at steady-state is 24 L/h.[L13347],The elimination half-life is 6.5 hours.[L13347],>70%.,None,NA,NA,Not recommended,NA,,
Cinnarizine,"Anti-emetic, Antivertigo","Calcium signaling pathway, Neuroactive ligand-receptor interaction",,,,,,,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,368.524,5.107,2,0,6,6.48,0,5.27,,,,-0.1,,,,0.6874,0.3702,31.02,,,,,,,1.77827941,-46.72737001,0.7943,37.7759,Inconclusive,0,3.330601675,0,0,Inactive,Inactive,3.16227766,-223.2866898,0,0,Inactive,0,4.823314883,0,0,Inactive,Inactive,0,1.614210273,,,,,,0,-38.41020557,,,,,,,0.3429925699,Oral,,,,,,,NA,NA,NA,Not recommended,NA,,
Tedizolid,Antibacterial,Ribosome- protein biosynthesis,,bacterial 50S ribosomal subunit inhibitor,,,,,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](CO)OC4=O)cc3F)cn2)n1,370.344,1.3957,8,1,4,106.26,1,11.24,,,,0.01,,,,,0.1987,14.33,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.3500974765,Oral; parenteral,"2.0 ± 0.7 (oral administration)
 2.3 ± 0.6 (intravenous administration)","Approximately 70 to 90% of tedizolid is bound to human plasma proteins.[L11232, A199050, A199152, A199155]","The volume of distribution for tedizolid following a single intravenous dose of 200 mg is between 67 and 80 L.[L11232] In a study involving oral administration of 200 mg tedizolid to steady-state, the volume of distribution was 108 ± 21 L, while a single 600 mg oral dose resulted in an apparent volume of distribution of 113.3 ± 19.3 L.[A199152, A199155] Tedizolid has been observed to penetrate the interstitial space of both adipose and skeletal muscle tissue and is also found in the epithelial lining fluid as well as in alveolar macrophages.[L11232, A199152, A199155]","Tedizolid has an apparent oral clearance of 6.9 ± 1.7 L/hr for a single dose and 8.4 ± 2.1 L/hr at steady-state. The systemic clearance is 6.4 ± 1.2 L/hr for a single dose and 5.9 ± 1.4 L/hr at steady-state.[L11232, A199140, A7642]","Tedizolid has a half-life of approximately 12 hours.[L11232, A199140, A7642]",0.91,Cyproheptadiene,NA,NA,Use with caution,NA,,
Treprostinil,"Anticoagulant, Antihypertensive, Vasodilator","Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation","P2RY12, PPARD, PTGIR",prostanoid receptor agonist,,,8.72,pEC50,CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O,390.52,3.5832,4,3,10,86.99,5,,,,,0.12,,,,,,12.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.3691869661,Oral; subcutaneous,,"Human plasma protein binding is approximately 91% in in vitro concentrations ranging from 330 to 10,000 &micro;/L.",0.23 L/kg,10.70 mL/min/kg,0.82 hours,~100 % (subcutaneous),None,Severe hepatic impairement,Category B3,Use with caution,None,,
Amisulpride,Antipsychotic,"Neuroactive ligand-receptor interaction, Dopaminergic synapse",DRD2,dopamine receptor antagonist,,,8.55,pKi,CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC,369.487,1.2851,6,2,7,101.73,1,9.47,,,,0.03,,,,0.09462,0.2622,22.02,,,,,,,0,-11.83258764,0,0,Inactive,0,-41.85628561,0,0,Inactive,Inactive,0,3.042740981,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,2.918712589,,,,,,0,-1.444791098,,,,,,,0.3802396818,Oral; Parenteral,"39 ± 3 and 54 ± 4 ng/mL (50 mg dose)
",Plasma protein binding ranges from 25% to 30% in the concentration range from 37 to 1850 ng/mL. Amisulpride distributes into erythrocytes,"Following oral administration, the volume of distribution is 5.8 L/kg. Following intravenous infusion, the mean volume of distribution of amisulpride is estimated to be 127 to 144 L in surgical patients and 171 L in healthy subjects.",The plasma clearance of amisulpride is 20.6 L/h in surgical patients and 24.1 L/h in healthy subjects following intravenous administration. Renal clearance was estimated to be 20.5 L/hr (342 mL/min) in healthy subjects.,Approximately 12 hours,48 %,None,Hypersensitivity,Category C,Not recommended ,NA,,
Agomelatine,Antidepressant,"Neuroactive ligand-receptor interaction, Circadian entrainment, Serotonergic synapse","HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B","melatonin receptor agonist, serotonin receptor antagonist",,,10.22,pKi,COc1ccc2cccc(CCNC(C)=O)c2c1,243.306,2.527,2,1,4,38.33,0,42.24,,,,-0.03,,,,,0.1484,14.2,,,,,,,0,-3.138230543,0,0,Inactive,0,-2.555753991,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-3.976563136,0,0,Inactive,Inactive,0,0.0987748557,,,,,,0,-6.490698419,,,,,,,0.3878803472,Oral,,> 95%,,,<2 hours,< 5%,NA,NA,Category B1,Not recommended,None,,
Nitisinone,Antityrosinemia,"Ubiquinone and other terpenoid-quinone biosynthesis, Tyrosine metabolism, Phenylalanine metabolism",,hydroxyphenylpyruvate dioxygenase inhibitor,,,,,O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-],329.23,2.7346,5,0,3,94.35,0,,,,,-0.1,,,,,0.2981,24.42,,,,,,,39.81071706,-131.7900216,39.8107,59.6712,Inconclusive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-0.2332275721,,,,,,0,-18.59799257,,,,,,,0.4163137943,Oral,,,,,~54 hours,90 %,NA,NA,Category B3,Not recommended,NA,,
Etoricoxib,NSAIDs,Arachidonic acid metabolism,PTGS2,cyclooxygenase inhibitor,,,6.1,pIC50,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,358.85,4.17592,4,0,3,59.92,0,12.43,,,,0.32,,,,0.1588,0.06952,22.4,,,,,,,0.7079457844,-52.54959883,0.7079,40.5712,Inconclusive,0,1.937852938,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.121620134,0,0,Inactive,Inactive,0,-1.052400261,,,,,,0,-20.24740092,,,,,,,0.4416904553,Oral,,92%,1.50 L/kg,0.79 mL/min/kg,26 hours,99 %,NA,NA,Category C,Not recommended,NA,,
Moclobemide,Antidepressant,"Serotonergic synapse, Dopaminergic synapse, Tryptophan metabolism, Phenylalanine metabolism, Tyrosine metabolism","MAOA, MAOB",monoamine oxidase inhibitor,,,,,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,268.744,1.402,3,1,4,41.57,0,-1.36,,,,0.01,,,,0.3217,0.1695,13.94,,,,,,,0,-75.97169548,0,0,Inactive,0,10.38585445,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.9273651984,0,0,Inactive,Inactive,0,-1.360573233,,,,,,0,-17.76346825,,,,,,,0.4775369276,Oral,,"Approximately 50% (primarily to albumin) [L1350]
",1.10 L/kg,10 mL/min/kg,1.50 hours,75 %,NA,NA,Category B3,Use with caution ,None,,
Safinamide,Antiparkinsonian,"Serotonergic synapse, Dopaminergic synapse",MAOB,"dopamine reuptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor",,,,,C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,302.349,2.3681,3,2,7,64.35,1,,,,,0.16,,,,0.3615,0.04637,12.51,,,,,,,0,0,0,0,Inactive,0,-44.11683162,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-7.405527314,0,0,Inactive,Inactive,0,-5.142339843,,,,,,0,-6.931474965,,,,,,,0.4884323461,Oral,,88–90%,2.19 L/kg,1.17 mL/min/kg,21.67 hours,0.95,Amitriptyline; amoxapine; amphetamine polistirex; clomipramine; cyclobenzaprine; cyproheptadine; desipramine; desvenlafaxine; deutetrabenazine; dexmethylphenidate; dextroamphetamine; dextromethorphan; diethylpropion; doxepin; duloxetine; fentanyl; fentanyl intranasal; fentanyl transdermal; fentanyl transmucosal; imipramine; isocarboxazid; levomilnacipran; linezolid; lisdexamfetamine; maprotiline; meperidine; methadone; methamphetamine; methylphenidate; milnacipran; morphine; nefazodone; nortriptyline; ozanimod; phendimetrazine; phenelzine; protriptyline; rasagiline; selegiline; selegiline transdermal; solriamfetol; St John's Wort; tapentadol; tramadol; tranylcypromine; trazodone; trimipramine; venlafaxine,"Swelling of lungs, oral mucosa; heoatic impairment",Category B3,Not recommended,NA,,
Tasimelteon,Hypnotic,"Neuroactive ligand-receptor interaction, Circadian entrainment","MTNR1A, MTNR1B",melatonin receptor agonist,,,9.8,pKi,CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2,245.322,2.2512,2,1,4,38.33,2,28.66,,,,-0.2,,,,,0.1536,7.34,,,,,,,0,-20.26376557,0,0,Inactive,0,-26.63688273,0,0,Inactive,Inactive,0,-74.42759341,0,0,Inactive,0,-8.454367117,0,0,Inactive,Inactive,0,-3.831770284,,,,,,0,-8.482150736,,,,,,,0.4944796058,Oral,,"At therapeutic concentrations, tasimelteon is about 90% bound to proteins.",0.33 L/kg,9.04 mL/min/kg,0.75 hours,,None,None,NA,Not recommended,None,,
Voxelotor,Anti-anemic,NA,,hemoglobin modulator,,,5.09,pEC50,CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,337.379,3.6231,6,1,6,77.24,0,4.85,,,,-0.09,,,,,0.1638,16.72,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5085750185,Oral,,"The protein binding of voxeletor is 99.8%, according to in vitro studies.[L10397]",The apparent volume of distribution of voxelotor in the central compartment is 338L and 72.2L in the plasma.[L10397],The apparent oral clearance of voxelotor is approximately 6.7 L/h.[L10397],"The plasma elimination half-life of voxelotor in sickle cell disease patients is about 35.5 hours, according to the FDA label.[L10397] The mean half-life in the red blood cell is 60 days. The average plasma half-life of voxelotor was 50 hours in patients with sickle cell disease, compared with 61–85 hours in healthy patients, in one clinical study.[A188126]",,lonafarnib,Hypersensitivity,NA,Not recommended,NA,,
Istradefylline,Antiparkinsonian,Neuroactive ligand-receptor interaction,"ADORA1, ADORA2A, ADORA2B, ADORA3",adenosine receptor antagonist,,,,,CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O,384.436,2.1241,8,0,6,80.28,0,-0.25,,,,0.09,,,,,0.1372,5.647,,,,,,,0.7079457844,-73.33593341,0.7079,49.827,Inconclusive,0,-2.996001756,0,0,Inactive,Inactive,0,1.789245937,0,0,Inactive,0,-1.832820499,0,0,Inactive,Inactive,0,5.210021728,,,,,,0,-18.97251207,,,,,,,0.5118960284,Oral,"181.1ng/mL 
M1, the primary active metabolite- 4.34ng/mL
The M8 metabolite- 12.6ng/mL ","Istradefylline is approximately 98% protein bound in plasma,[A184064] mostly to serum albumin and alpha-1-acid glycoprotein.[L8225]",The apparent volume of distribution of istradefylline is 448-557L.[A184064],The apparent clearance of istradefylline is 4.1-6.0L/h.[A184064],"The terminal elimination half life of istradefylline was 64-69 hours.[A184064,A184067]",,None,None,NA,Use with caution,NA,,
Amifampridine,Autoimmune disease treatment,NA,,potassium channel blocker,,,,,Nc1ccncc1N,109.132,0.246,3,2,0,64.93,0,5.4,,,,-0.16,,,,,0.1603,35.62,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5496197449,Oral,16 to 137 ng/mL,There is no human data on serum protein binding of amifampridine [A33863].,"In rats, orally-administered amifampridine was extensively absorbed in the gastrointestinal tract and widely distributed. Drug concentrations were highest in organs of excretion, including liver, kidney and the gastrointestinal tract, and some tissues of glandular function, such as lacrimal, salivary, mucous, pituitary and thyroid glands [F272]. Concentrations in tissues are generally similar to or greater than concentrations in plasma [F272].",it is mostly cleared from the plasma via metabolism by N-acetylation [F272].|Overall clearance of amifampridine is both metabolic and renal,The plasma elimination half-life is approximately 2.5 hours for amifampridine and 4 hours for 3-N-acetylamifampridine [F272].,93-100%,None,Hypersensitivity; seizures,Category C,Use with caution,NA,,
Revefenacin,Antiasthmatic,"Neuroactive ligand-receptor interaction, Cholinergic synapse",,cholinergic receptor antagonist,,,9.75,pKi,CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1,597.76,4.836,6,2,10,108.21,0,,,,,0,,,,,,7.44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.55014236,Inhalation,0.02-0.15 ng/ml,The protein binding of revefenacin and its active metabolite is of 71% and 42% respectively.[FDA label],"After intravenous administration of revefenacin, the reported volume of distribution is 218 L which suggests an extensive distribution to the tissues.[FDA label]","The renal clearance of revefenacin is negligible and thus, the clearance rate is not a major parameter for this drug.",The apparent terminal half-life of a dose of 350 mcg of revefenacin was 22.3-70 hours.[A40025],,None,Hypersensitivity,NA,Use with caution,NA,,
Tezacaftor,CFTR modulator,ABC transporters,,CFTR channel agonist,,,,,CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO,520.504,3.3953,7,4,8,113.18,1,-1.16,,,,-0.07,,,,,0.1873,3.48,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,6.212447154,,,,,,0,-8.555862058,,,,,,,0.5556265701,Oral,5.95 mcg/ml (when administered with tezacaftor),"Tezacaftor is approximately 99% bound to plasma proteins, mainly albumin.[L6814]",The apparent volume of distribution of tezacaftor was 271 L in a study of patients in the fed state who received 100 mg of tezacaftor every 12 hours.[L6814],The apparent clearance of tezacaftor has been measured at 1.31 L/h for patients in the fed state during a clinical trial.[A32094],"The apparent half-life of tezacaftor is approximately 57.2 hours.[A179665,L6829]",,lonafarnib,None,Category B3,Use with caution,NA,,
Lemborexant,Hypnotic,Neuroactive ligand-receptor interaction,"HCRTR1, HCRTR2",orexin receptor antagonist,,,8.52,pKi,Cc1ncc(OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1,410.424,3.74204,5,1,6,77,2,15.02,,,,-0.18,,,,,,24.6,,,,,,,0,0,,,,0,-14.16892565,,,,,,,,,,,,,,,,0,-10.77543886,,,,,,0,-9.194696294,,,,,,,0.5650737637,Oral,,"Lemborexant is approximately 94% protein-bound _in vitro_, though the specific proteins to which it binds in plasma have not been elucidated.[L10863]","The volume of distribution of lemborexant is 1970 L, indicating extensive tissue distribution.[L10863]",,"The half-life for lemborexant at doses of 5mg and 10mg is 17 and 19 hours, respectively.[L10863]",,None,Narcolepsy,Category B3,Not recommended,None,,
Riluzole,Nerve cells protectant,"Neuroactive ligand-receptor interaction, Glutamatergic synapse, Dopaminergic synapse","KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",glutamate inhibitor,,,,,Nc1nc2ccc(OC(F)(F)F)cc2s1,234.202,2.7771,4,1,1,48.14,0,4.91,,,,-0.15,,,,,0.1438,7.161,,,,,,,0,13.72442103,0,0,Inactive,8.912509381,-51.37292463,0,0,Inactive,Inactive,0,-19.04576936,0,0,Inactive,0,-130.1703106,0,0,Inactive,Inactive,0,-3.60044197,,,,,,0,0.9635580679,,,,,,,0.5754420286,Oral,,"96% bound to plasma proteins, mainly to albumin and lipoprotein over the clinical concentration range.",3.50 L/kg,11.30 mL/min/kg,The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.,64 %,None,Hypersensitivity,Category B3,Not recommended,NA,,
Tamsulosin,Antidysuria,"cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D",adrenergic receptor antagonist,,,,,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,408.52,2.3409,6,2,11,99.88,1,,,,,-0.07,,,,,0.1193,22.04,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6298348541,Oral,"3.1-5.3ng/mL (0.4mg oral dose) 
2.5-3.6ng/mL (0.8mg oral dose)","Tamsulosin is 94%-99% protein bound, mostly to alpha-1-acid glycoprotein.[Label]",0.21 L/kg,0.62 mL/min/kg,6.80 hours,99 %,Ombitasvir/paritaprevir/ritonavir & dasabuvir,Hypersensitivity,Category B2,NA,NA,,
Relugolix,"Antineoplastic, Anti-endometriosis","Neuroactive ligand-receptor interaction, GnRH signaling pathway",,gonadotropin releasing factor hormone receptor antagonist,,,,,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,623.642,3.7505,11,2,9,132.61,0,,,,,-0.04,,,,,,3.22,,,,,,,0,-5.77358573,,,,0,-37.80712732,,,,,,,,,,,,,,,,0,12.98535768,,,,,,0,-3.768845717,,,,,,,0.6363492566,Oral,70 (± 65) ng/mL,"Relugolix is 68-71% protein-bound in plasma, primarily to albumin and, to a lesser extent, α1-acid glycoprotein.[L27991]",,The average renal clearance of relugolix is 8 L/h with a total clearance of 26.4 L/h.[L27991],"The average effective half-life of relugolix is 25 hours, while the average terminal elimination half-life is 60.8 hours.[L27991]",0.12,None,None,NA,No sufficient information is available,NA,,
Paritaprevir,Antiviral,Protein biosynthesis,,HCV inhibitor,,,,,Cc1cnc(C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3CC3)NC(=O)[C@@H]3C[C@@H](Oc4nc5ccccc5c5ccccc45)CN3C2=O)cn1,765.893,3.63692,10,3,7,189.65,5,0.28,,,,-0.17,,,,,0.151,14.05,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,-5.94618196,,,,,,0,-18.50535767,,,,,,,0.6399809719,Oral,194 ng/mL ,97 to 98.6% bound to human plasma proteins [FDA Label].,1.37 L/kg,5.74 mL/min/kg,8.71 hours,,NA,NA,NA,Not recommended,NA,,
Venetoclax,Antineoplastic,Apoptosis,BCL2,BCL inhibitor,,,11,pKi,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,868.457,8.6599,11,3,13,172.03,0,,,,,-0.29,,,,,0.1129,21.72,,,,,,,0,-15.92084643,,,,0,6.775515142,,,,,,,,,,,,,,,,0,12.36723935,,,,,,2.238721139,-111.5573818,,,,,,,0.7787486947,Oral,2.1 ± 1.1 μg/mL,Venetoclax is highly bound to human plasma protein with unbound fraction in plasma <0.01 across a concentration range of 1-30 µM (0.87-26 µg/mL). The mean blood-to-plasma ratio was 0.57 [FDA label].,The population estimate for apparent volume of distribution (Vdss/F) of venetoclax ranged from 256-321 L [FDA label].,Mainly hepatic [FDA label].,"The half-life of venetoclax is reported to be 19-26 hours, after administration of a single 50-mg dose [A40022], [FDA label].",,"Atazanavir
Clarithromycin
Cobicistat
Conivaptan
Darunavir
Fosamprenavir
Grapefruit
Idelalisib
Imatinib
Indinavir
Isoniazid
Itraconazole
Ketoconazole
Lopinavir
Nefazodone
Nelfinavir
Nicardipine
Posaconazole
Ritonavir
Saquinavir
Tipranavir
Voriconazole
",Strong CYP3A inhibitors at initiation and during ramp-up phase,Category C,Not recommended,None,,
Osilodrostat,Antihypertensive,"Steroid hormone biosynthesis, Aldosterone synthesis and secretion",,cytochrome P450 inhibitor,,,8.6,pIC50,N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1,227.242,2.42948,3,0,1,41.61,1,,,,,-0.11,,,,,,-5.55,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7825055362,Oral,,"Both osilodrostat and its M34.5 metabolite are minimally protein-bound in plasma at less than 40%.[L12123,L12132] The extent of protein-binding is independent of drug concentration.[L12132] The specific plasma proteins to which osilodrostat binds have not been elucidated.",The median apparent volume of distribution of osilodrostat is 100 L.[L12123],Data regarding the oral clearance of osilodrostat are not currently available.,"The elimination half-life of osilodrostat is approximately 4 hours.[L12123,A191850]",,Lefamulin,None,NA,Not recommended,NA,,
Uridine triacetate,"Antidote (5-fluorouracil, capecitabine)",NA,,,,,,,CC(=O)OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O,370.314,-1.1395,10,1,5,142.99,4,-22.84,,,,-0.02,,,,,0.05866,6.896,,,,,,,0,-151.4011888,0,0,Inactive,0,-6.166535387,0,0,Inactive,Inactive,0,-23.31442524,0,0,Inactive,0,-0.1943550294,0,0,Inactive,Inactive,0,2.009423624,,,,,,0,-40.73074348,,,,,,,0.7875121617,Oral,,,"Circulating uridine is taken up into mammalian cells via specific nucleoside transporters, and also crosses the blood brain barrier.",,2 to 2.5 hours,,NA,NA,NA,Use with caution,NA,,
Epinastine,Antiallergic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",HRH1,histamine receptor antagonist,,,,,NC1=NCC2c3ccccc3Cc3ccccc3N12,249.317,2.4668,3,1,0,41.62,1,-3.27,,,,-0.08,,,,,-0.03911,-4.851,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8145038482,Oral; Ophthalmic,,64%,,* 56 L/hr [patients with allergic conjunctivitis receiving one drop of ELESTAT® ophthalmic solution in each eye twice daily for seven days],12 hours,0.4,NA,Hypersensitivity; contact lens related irritation,Category C,Use with caution,NA,,
Varenicline,Smoking cessation adjunct,"Neuroactive ligand-receptor interaction, Cholinergic synapse","CHRNA3, CHRNA4, CHRNA6, CHRNA7",acetylcholine receptor agonist,,,,,c1cnc2cc3c(cc2n1)C1CNCC3C1,211.268,1.8039,3,1,0,37.81,2,,,,,-0.17,,,,,,22.78,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8751977222,Oral,,Less than 20%.,,,The elimination half-life of varenicline is approximately 24 hours,87 %,None,Hypersensitivity,Category B3,Not recommended,NA,,
RANOLAZINE,Vasodilator,NA,"SCN10A, SCN9A",sodium channel blocker,,,,,COc1ccccc1OCC(O)CN1CCN(CC1)CC(=O)Nc1c(C)cccc1C,427.545,2.30804,6,2,9,74.27,1,,,,,,,,,1.095,0.1142,,,,,,,,39.81071706,-8.402266838,39.8107,43.5234,Inconclusive,0,2.646338673,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-1.24390448,,,,,,0,-28.54426624,,,,,,,0.3107606771,Oral,2600 ng/mL,Approximately 62% of the administered dose of ranolazine is bound to plasma proteins. Ranolazine appears to have a higher binding affinity for alpha-1 acid glycoprotein,1.20 L/kg,9.50 mL/min/kg,1.80 hours,42.50 %,"Ceritinib
Cobicistat
Darunavir
Efavirenz
Eliglustat
Itraconazole
Ketoconazole
Lefamulin
Ribociclib
","Hepatic cirrhosis, including Child-Pugh class A (mild), B (moderate), and C (severe)",Category C,Not recommended,None,,
DOMPERIDONE,"Anti-emetic, Prokinetic","Neuroactive ligand-receptor interaction, Dopaminergic synapse","DRD2, DRD3",dopamine receptor antagonist,,,,,Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CCCn2c(=O)[nH]c3ccccc23)CC1,425.92,3.3532,5,2,5,78.82,0,4.8,,,,-0.11,,,,0.39,0.1608,7.05,,,,,,,11.22018454,-39.77118128,11.2202,59.4962,Inconclusive,0,-6.119265208,0,0,Inactive,Inactive,39.81071706,-14.0227329,39.8107,48.0964,Inconclusive,39.81071706,-9.588627326,39.8107,31.8879,Inconclusive,Cytotoxic,0,16.13006403,,,,,,0,-32.77258697,,,,,,,0.4729268022,Oral; parenteral,,91%-93%,3.40 L/kg,9.50 mL/min/kg,7.50 hours,15 %,NA,NA,Category B2,Not recommended,NA,,
PILOCARPINE NITRATE,Miotic,"Neuroactive ligand-receptor interaction, Cholinergic synapse, Salivary secretion","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",acetylcholine receptor agonist,,,6.97,pEC50,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,271.273,0.8141,6,1,3,107.49,2,,,,,,,,,,0.1136,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5852557673,Oral; Ophthalmic,,,,,0.76 hours,,None,"Uncontrolled asthma, anterior eye inflammation, any time miosis in undesirable",Category B3,Use with caution,None,,
TRIMETHOBENZAMIDE HYDROCHLORIDE,Anti-emetic,NA,DRD2,histamine receptor antagonist,,,,,COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,424.925,3.0046,6,1,10,69.26,0,,,,,,,,,,0.1981,,,,,,,,0,-3.977884476,0,0,Inactive,0,3.390053047,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.168830665,0,0,Inactive,Inactive,0,11.68802218,,,,,,0,-31.32842639,,,,,,,0.2437311936,Oral; Parenteral,,,,,The mean elimination half-life of trimethobenzamide is 7 to 9 hours.,80 %,None,Hypersensitivity,NA,Not recommended,NA,,
BENZOIC ACID,"Antifungal, Antiseptic",NA,"DAO, HRSP12, PRDX5, RAB9A",food preservative,,,,,OC(=O)c1ccccc1,122.123,1.3848,1,1,1,37.3,0,33.07,,,,-0.19,,,,,,7.99,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5234500291,Oral; Topical,,,,,,,NA,NA,NA,NA,NA,,
UREA,"Diuretic, Emollient, Keratolytic",NA,"ARG1, CA2, CTNNB1","hydroxy radical formation stimulant
",,,,,NC(=O)N,60.056,-0.9762,1,2,0,69.11,0,19.36,,,,-0.03,,,,,0.04168,18.24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5533634605,?,,,,,,,None,Hypersensitivity; Viral skin disease,NA,NA,NA,,
MICONAZOLE NITRATE,Antifungal,Steroid biosynthesis,"TRPM2, TRPV5",bacterial cell wall synthesis inhibitor,,,,,Clc1ccc(COC(Cn2cncc2)c2ccc(Cl)cc2Cl)c(Cl)c1,479.147,6.1071,5,1,6,90.42,1,,,,,-0.27,,,,-0.1193,0.003347,14.26,,,,,,,31.6227766,-16.23344465,,,,0,-28.58427325,,,,,,,,,,,,,,,,0,3.535249746,,,,,,12.58925412,-75.55954881,,,,,,,0.9388745955,Oral; Topical; Vaginal,"15.1 ± 16.2 mcg/mL (oral)
10.71 ng/mL (vaginal) ",,7.14 L/kg,9.48 mL/min/kg,19.75 hours,25 %,NA,Hypersensitivity; milk protein allergy,Category A,Use with caution,NA,,
TIOPRONIN,Antidote (mercury),NA,,"chelating agent, reducing agent",,,,,CC(S)C(=O)NCC(=O)O,163.198,-0.4945,3,3,3,66.4,1,,,,,0.15,,,,,0.1099,24.6,,,,,,,0,-71.84311816,0,0,Inactive,0,-20.40846769,0,0,Inactive,Inactive,0,0.9856225813,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,1.195151158,,,,,,0,-14.09262405,,,,,,,0.4699543109,Oral,,Tiopronin undergoes extensive protein binding in plasma. It is thought that this occurs through the formation of a disulphide bridge to the free thiol group of albumin.,1.39 L/kg,1.48 mL/min/kg,55 hours,63 %,None,Hypersensitivity,NA,Not recommended,NA,,
MIANSERIN HYDROCHLORIDE,Antidepressant,Neuroactive ligand-receptor interaction,"ADRA1A, ADRA1B, ADRA1D, HRH1, HRH2, HTR2A, HTR2B, HTR2C, HTR6, HTR7",serotonin receptor antagonist,,,8.12,pKi,CN1CCN2C(C1)c1ccccc1Cc1ccccc21,300.833,3.5057,2,0,0,6.48,1,,,,,,,,,,0.2217,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.1925777332,Oral,,90%,13.75 L/kg,21.90 mL/min/kg,9.60 hours,22 %,NA,NA,Category B2,Not recommended,NA,,
BETAHISTINE HYDROCHLORIDE,"Antivertigo, Vasodilator","Calcium signaling pathway, Neuroactive ligand-receptor interaction","HRH1, HRH3","histamine receptor agonist, histamine receptor antagonist",,,,,CNCCc1ccccn1,209.12,1.6871,2,1,3,24.92,0,,,,,,,,,,0.1802,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.297893681,Oral,,<5%,"In a pharmacokinetic study of rats, betahistine was found to be distributed throughout the body.[L16443] Human data for betahistine's volume of distribution is not readily available.[A220438,A220563,L16388,L16443]",,"The half-life of betahistine is 3-4 hours.[A220438,A220563,L16388]",,NA,NA,Category B3,Not recommended,NA,,
BIFONAZOLE,Antifungal,Steroid biosynthesis,,sterol demethylase inhibitor,,,,,c1ccc(cc1)c1ccc(cc1)C(c1ccccc1)n1ccnc1,310.4,5.1878,2,0,4,17.82,1,70.75,,,,-0.11,,,,-0.0446,,-1.13,,,,,,,31.6227766,-23.28488786,31.6228,80.4844,Inconclusive,39.81071706,-10.76359729,39.8107,38.2072,Inconclusive,Cytotoxic,39.81071706,-31.39313483,39.8107,107.675,Inconclusive,0,-10.01068622,0,0,Inactive,Inactive,0,8.893974694,,,,10,36.432,12.58925412,-76.81131184,,,,,14.125375,24.488,0.5805087831,Oral; Topical,,,,,1-2 hours,,NA,NA,Category B3,NA,None,,
ENOXACIN,Antibacterial,DNA synthesis/replication,TOP2A,topoisomerase inhibitor,,,,,CCn1cc(C(=O)O)c(=O)c2cc(F)c(nc12)N1CCNCC1,320.324,0.6633,6,2,3,87.46,0,-14.27,,,,-0.12,,,,1.182,,7.669,,,,,,,0,-42.60789196,0,0,Inactive,0,-11.77321733,0,0,Inactive,Inactive,0,-97.27821453,0,0,Inactive,0,2.67367584,0,0,Inactive,Inactive,0,-0.3580024603,,,,,,0,-32.15012181,,,,,,,0.6023847024,Oral,,,2 L/kg,5.40 mL/min/kg,5.10 hours,87 %,NA,NA,Category B3,Not recommended,NA,,
Rilpivirine,Anti-HIV,NA,"NR1I2, SCN10A",non-nucleoside reverse transcriptase inhibitor,,,,,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,366.428,4.9891,6,2,5,97.42,0,82.1,,,,1.73,,,,,0.1167,-36.34,,,,,,,22.38721139,-49.40789163,22.3872,115.464,Active,28.18382931,-35.58664217,35.4813,42.7423,Inconclusive,Cytotoxic,39.81071706,-70.035117,39.8107,106.141,Inconclusive,15.84893192,-44.46915358,15.8489,42.0715,Inconclusive,Cytotoxic,0,-1.512509932,,,,,,8.912509381,-80.52372913,,,,,,,0.2394370022,Oral; Parenteral,"247 ng/mL (healthy subjects)
138.6 ng/mL (HIV patients)","Rilpivirine is highly protein-bound thus, >99% of its dose can be bound to plasma protein in a concentration-dependent manner.[A31331] The most important plasma binding proteins is albumin.[FDA label]","In VIH-1 patients, the apparent volume of distribution in the central compartment was determined to be 152-173 L.[L1032]","In HIV-1 patients, the apparent oral clearance is estimated to be 10.5-11.8 L/h.[L1032]","Plasma drug elimination is really slow, giving rilpivirine a half-life of 34-55 hours after oral administration.[A31331]",,Carbamazepine; dexamethasone; dexlansoprazole; efavirenz;elvitegravir/cobicistat/emtricitabine/tenofovir DF; eslicarbazepine acetate; esomeprazole; etravirine; fosphenytoin; lansoprazole; nevirapine; omeprazole; oxcarbazepine; pantoprazole; phenobarbital; phenytoin; rabeprazole; rifampin; rifapentine; St John's Wort,Hypersensitivity,Category B1,Not recommended,NA,,
Cabergoline,"Antiparkinsonian, Antidyskinetic","Neuroactive ligand-receptor interaction, Dopaminergic synapse, Prolactin signaling pathway","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7",dopamine receptor agonist,,,9.2,pKi,C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)CC2c3cccc4[nH]cc(c34)C[C@H]21,451.615,3.1939,4,2,8,71.68,3,,,,,0.2,,,,,,15.57,,,,,,,19.95262315,-98.1251517,19.9526,97.926,Inconclusive,0,2.204313515,0,0,Inactive,Inactive,35.48133892,-0.3451302699,35.4813,47.3171,Inconclusive,0,0.1528995094,0,0,Inactive,Inactive,12.58925412,68.72586133,,,,,,0,-33.75430762,,,,,,,0.294052515,Oral,,Moderately bound (40% to 42%) to human plasma proteins in a concentration-independent manner.,,"* renal cl=0,008 L/min
 * nonrenal cl=3.2 L/min",The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,65 %,"almotriptan
eletriptan
frovatriptan
glyceryl trinitrate pr
naratriptan
nitroglycerin IV
nitroglycerin sublingual
nitroglycerin topical
nitroglycerin transdermal
nitroglycerin translingual
rizatriptan
sumatriptan
sumatriptan intranasal
zolmitriptan","Uncontrolled hypertension
Hypersensitivity to ergot derivatives
Severe hepatic disease",Category B1,Not recommended,None,,
Acrivastine,Antiallergic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",HRH1,histamine receptor antagonist,,,,,Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1,348.446,4.01532,3,1,6,53.43,0,28.58,,,,0.05,,,,,0.1912,11.52,,,,,,,39.81071706,-18.66364175,39.8107,30.2251,Inconclusive,0,3.466940646,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,3.21311899,0,0,Inactive,Inactive,0,-0.6866576426,,,,,,0,-32.0431464,,,,,,,0.294793256,Oral,,Acrivastine binding to human plasma proteins was 50 ± 2.0%.,0.46 ± 0.05 L/kg,2.9 ± 0.7 mL/min/kg,The mean terminal half-life for acrivastine was 1.9 ± 0.3 hours following single oral doses and increased to 3.5 ± 1.9 hours at steady state. The terminal half-life for the propionic acid metabolite was 3.8 ± 1.4 hours.,18 %,Dihydroergotamine; dihydroergotamine inhaled; dihydroergotamine intranasal; ergoloid mesylates; ergonovine; ergotamine; isocarboxazid; linezolid; methylergonovine; phenelzine; procarbazine; rasagiline; selegiline; selegiline transdermal; tranylcypromine,Hypersensitivity; severe hypertention,NA,Use with caution,NA,,
Elvitegravir,Anti-HIV,NA,,HIV integrase inhibitor,,,,,COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C,447.89,4.281,5,2,7,88.76,1,7.47,,,,0.46,,,,,0.1404,10.31,,,,,,,0.0011220185,-356.1835003,0,0,Inactive,0,3.679002689,0,0,Inactive,Inactive,12.58925412,-222.6469686,12.5893,80.6309,Active,0,0,0,0,Inactive,Inactive,0,-1.420278371,,,,,,10,-80.60074756,,,,,,,0.3353710948,Oral,,Elvitegravir is 98–99% bound to human plasma proteins,,,The median terminal plasma half-life following administration of elvitegravir and ritonavir was approximately 8.7 hours.,,NA,NA,Category B2,Not recommended,NA,,
Dasabuvir,Antiviral,NA,,HCV inhibitor,,,,,COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C,493.585,4.0236,6,2,5,110.26,0,-10.02,,,,0.55,,,,0.184,0.3029,17.1,,,,,,,5.011872336,-79.47204571,5.0119,32.765,Inconclusive,0,-3.990996553,0,0,Inactive,Inactive,39.81071706,-109.4435869,39.8107,63.7795,Inconclusive,0,0.5959875143,0,0,Inactive,Inactive,12.58925412,39.48904639,,,,12.589254,48.664,3.981071706,-41.59730306,,,,,14.125375,42.532,0.4206438181,Oral ,,Dasabuvir is greater than 99.5% bound to human plasma proteins [FDA Label].,2.13 L/kg,Clearance of Dasabuvir has not been determined.,5.70 hours,The absolute bioavailability of Dasabuvir is 70%.,NA,NA,NA,Use with caution,NA,,
Silodosin,Antidysuria,"cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D",adrenergic receptor antagonist,,,10.44,pKi,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,495.542,3.0711,6,3,13,97.05,1,-9.07,,,,-0.03,,,,0.8702,0.3783,18,,,,,,,39.81071706,-10.39907817,39.8107,47.6829,Inconclusive,0,-3.945999149,0,0,Inactive,Inactive,0,-2.210205697,0,0,Inactive,0,-37.71000725,0,0,Inactive,Inactive,0,-2.973387895,,,,,,0,-19.97735486,,,,,,,0.4221375037,Oral,"Following oral administration of silodosin 8 mg once daily in healthy male subjects, Cmax was 61.6 ± 27.54 ng/mL and AUC was 373.4 ± 164.94 ng x hr/mL. The Tmax was 2.6 ± 0.90 hours.7 Silodosin glucuronide or KMD-3213G, the main metabolite of silodosin, has an AUC three- or four fold higher than for the parent compound; A moderate fat or calorie meal reduces Cmax by 18% to 43% and AUC by 4% to 49",97% bound to protein ,49.5 L,2.80 mL/min/kg,3.60 hours,32 %,"itraconazole
ombitasvir/paritaprevir/ritonavir & dasabuvir","Hypersensitivity
Severe renal impairment (CrCl <30 mL/min)
Severe hepatic impairment (Child-Pugh Score >10)",Category B3,Not recommended,None,,
Lumacaftor,CFTR corrector,"ABC transporters, Gastric acid secretion, Pancreatic secretion, Bile secretion",CFTR,CFTR channel agonist,,,6.46,pEC50,Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1,452.413,4.74702,5,2,5,97.75,0,37.26,,,,0.02,,,,,0.04797,2.625,,,,,,,3.16227766,-55.89001864,3.1623,43.2008,Inconclusive,0,0.1680592001,0,0,Inactive,Inactive,0,-51.75491424,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,6.258826113,,,,,,0,-16.9324573,,,,,,,0.4816664437,Oral,Peak plasma concentrations reached at 4 h following administration,"Lumacaftor is extensively protein bound in the plasma (99%), and binds primarily to albumin.[FDA Label]","Following oral administration of 200 mg of lumacaftor every 24 hours to cystic fibrosis patients in a fed state for 28 days, the mean (+/-SD) for apparent volumes of distribution was 86.0 (69.8) L.[FDA Label]","The typical apparent clearance, CL/F (CV), of lumacaftor was estimated to be 2.38 L/hr.[FDA Label]",The half-life of lumacaftor is approximately 26 hours.[FDA Label],,Bosentan; carbamazepine; cariprazine; cobimetinib; dabrafenib; dexamethasone; doravirine; efavirenz; elbasvir/grazoprevir; enzalutamide; eslicarbazepine acetate; etravirine; fosphenytoin; fostemsavir; isavuconazonium sulfate; lonafarnib; lorlatinib; mitotane; nafcillin; nevirapine; oxcarbazepine; pentobarbital; phenobarbital; phenytoin; primidone; rifabutin; rifampin; rifapentine; St John's Wort,None,Category B3,Not recommended,NA,,
Stiripentol,Anticonvulsant,NA,GABRA3,GABA uptake inhibitor,,,,,CC(C)(C)C(O)/C=C/c1ccc2c(c1)OCO2,234.295,2.8355,3,1,2,38.69,1,2.28,,,,0.04,,,,0.1907,,23.97,,,,,,,39.81071706,-16.71890475,39.8107,57.344,Inconclusive,0,-13.23716458,0,0,Inactive,Inactive,0,2.4004399,0,0,Inactive,0,1.623265504,0,0,Inactive,Inactive,0,-1.94764978,,,,,,0,-30.55666365,,,,,,,0.4911907206,Oral,,Stiripentol binds extensively to circulating plasma proteins (about 99%) [L880].,The average volume of distribution is 1.03 L/kg but does not display a dose-dependent relationship. It is expected to be distributed into the extravascular space and with a high degree of tissue binding,"Plasma clearance decreases markedly at high doses| it falls from approximately 40 L/kg/day at the dose of 600 mg/day to about 8 L/kg/day at the dose of 2,400 mg [L880]. Decreased clearance is probably explained by inhibition of the cytochrome P450 isoenzymes that catalyzes stiripentol metabolism [L880].","Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].",,Finerenone; idelalisib; isavuconazonium sulfate; lonafarnib; voclosporin,NA,Category B3,Not recommended,NA,,
Pretomanid,Antibacterial (tuberculostatic),NA,FASN,nitric oxide donor,,,,,O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(OC(F)(F)F)cc1)C2,359.26,2.6677,7,0,5,88.65,1,-0.06,,,,0.08,,,,,,-11.24,,,,,,,0,-5.306319602,,,,0,-7.176977968,,,,,,,,,,,,,,,,0,-3.708231357,,,,,,0,-20.22684312,,,,,,,0.5265836265,Oral,"The steady-state Cmax of pretomanid was estimated to be 1.7 μg/mL after a single 200mg oral dose; In a separate pharmacokinetic modeling study, the Cmax of a 200mg dose was 1.1 μg/ml",The plasma protein binding of pretomanid is about 86.4%.[L8048],A pharmacokinetic modeling study estimated the volume of distribution at 130 ± 5L.[A182888] A pharmacokinetic study in healthy volunteers determined a volume of distribution of about 180 ± 51.3L in fasted state and 97.0 ± 17.2L in the fed state.[L8048],"The clearance of pretomanid in a pharmacokinetic simulation study has been estimated at 4.8 ± 0.2 liters/h.[A182888]
 According to the FDA label, the clearance of a single 200 mg oral dose of pretomanid is estimated to be 7.6 liters/h in the fasted state, and 3.9 liters/h in the fed state.[L8048]",The elimination half-life was determined to be 16.9-17.4 hours in a pharmacokinetic study of healthy subjects.[L8048] An FDA briefing document reports a half-life of 18 hours.[L8057],,None,None,NA,Use with caution,NA,,
Rufinamide,Anticonvulsant,Dopaminergic synapse,"GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",voltage-gated sodium channel blocker,,,,,NC(=O)c1cn(Cc2c(F)cccc2F)nn1,238.197,0.7035,4,1,3,73.8,0,-10.47,,,,-0.04,,,,0.3352,0.1638,-8.338,,,,,,,0,-95.86933835,0,0,Inactive,0,0.2521660134,0,0,Inactive,Inactive,0,-18.7064035,0,0,Inactive,0,-5.001427267,0,0,Inactive,Inactive,0,0.0821963921,,,,,,0,-14.46471419,,,,,,,0.5738176966,Oral,"Tmax, fed and fasted states= 4-6 hours; Cmax, 10 mg/kg/day= 4.01 µL/mL; Cmax, 30mg/kg/day= 8.68 µL/mL; AUC (0h-12h), 10mg/kg/day= 37.8±47 µg·h/mL; AUC (0h-12h), 30mg/kg/day= 89.3±59 µg·h/mL",26.3% - 34.8% with 90% binding to albumin (27%).,"Rufinamide was evenly distributed between erythrocytes and plasma. The apparent volume of distribution is dependent upon dose and varies with body surface area. The apparent volume of distribution was about 50 L at 3200 mg/day.
 Volume of distribution is similar between adults and children and is non-linear.",,"Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.",85 %,None,Hypersensitivity; Familial short QT syndrome,Category B3,Not recommended,NA,,
(+)-Camphor,"Analgesic, Anti-inflammatory, Antipruritic",NA,,,,,,,CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2,152.237,2.4017,1,0,0,17.07,2,4.08,,,,-0.14,,,,,,28.93,,,,,,,0,-14.17479775,0,0,Inactive,0,4.789257107,0,0,Inactive,Inactive,0,-11.39899869,0,0,Inactive,0,-18.47225354,0,0,Inactive,Inactive,0,-3.329756105,,,,,,0,-11.52310881,,,,,,,0.6421449108,,,,,,,,Artemether/lumefantrine; cariprazine; cobimetinib; dienogest/estradiol valerate; doravirine; elbasvir/grazoprevir; elvitegravir/cobicistat/emtricitabine/tenofovir DF; lonafarnib; lumacaftor/ivacaftor; lumefantrine; lurasidone; naloxegol; ombitasvir/paritaprevir/ritonavir & dasabuvir; oxcarbazepine; panobinostat; praziquantel; regorafenib; rilpivirine; roflumilast; vandetanib,Hypersensitivity,NA,NA,NA,,
Parecoxib,NSAIDs,Arachidonic acid metabolism,LTF,cyclooxygenase inhibitor,,,8.3,pIC50,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,370.43,3.53192,5,1,5,89.27,0,5.85,,,,-0.11,,,,,0.03281,24.92,,,,,,,0,-16.32548116,0,0,Inactive,0,1.429513781,0,0,Inactive,Inactive,0,-0.6025386063,0,0,Inactive,0,2.12911487,0,0,Inactive,Inactive,0,-0.7356438913,,,,,,0,-16.28390815,,,,,,,0.6736565492,,,98%,,,22 minutes (parecoxib)| 8 hours (valdecoxib),,NA,NA,Category C,Not recommended,None,,
Saxagliptin,Antidiabetic,Protein digestion and absorption,DPP4,dipeptidyl peptidase inhibitor,,,9.22,pKi,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,315.417,1.15798,4,2,2,90.35,8,-4.62,,,,0,,,,,,2.652,,,,,,,0,-12.63407141,0,0,Inactive,0,-2.820517765,0,0,Inactive,Inactive,0,8.056316388,0,0,Inactive,0,-0.7186755165,0,0,Inactive,Inactive,0,8.086467056,,,,,,0,5.661891902,,,,,,,0.6904239589,Oral,"Following a 5 mg single oral dose of saxagliptin to healthy subjects, the mean plasma AUC values for saxagliptin and its active metabolite were 78 ng•h/mL and 214 ng•h/mL, respectively. The corresponding plasma Cmax values were 24 ng/mL and 47 ng/mL, respectively.",The in vitro protein binding of saxagliptin and its active metabolite in human serum is negligible (<10%).,1.80 L/kg,7.10 mL/min/kg,7.50 hours,"Bioavailability, 2.5 - 50 mg dose = 67%",None,Hypersensitivity,Category B3,Use with caution,None,,
Bosutinib,Antineoplastic,ErbB signaling pathway,"ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK","Abl kinase inhibitor, Bcr-Abl kinase inhibitor, SRC inhibitor",,,10.54,pKd,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,530.456,5.19038,8,1,9,82.88,0,18.71,,,,-0.33,,,,-0.3065,0.09732,-1.12,,,,,,,3.16227766,-96.63655942,,,,14.12537545,-83.00742285,,,,,,,,,,,,,,,,0,-8.977021767,,,,,,7.943282347,-117.5169597,,,,,,,0.7121201366,Oral,"For 500mg dosage, max = 200 ng/mL; AUC = 3650 ng∙h/mL",94% bound to human plasma proteins in vitro. 96% bound to human plasma proteins in healthy subjects ex vivo. Extent of protein binding is not concentration-dependent. ,Apparent volume of distribution = 6080 ± 1230 L.,"Mean clearance (CL/F), single oral dose, fed-state = 189 L/h","Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours",,lefamulin,Hypersensitivity,NA,Not recommended,None,,
Selexipag,"Antihypertensive, Vasodilator","Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation",PTGIR,"IP1 prostacyclin receptor agonist, platelet aggregation inhibitor",,,,,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,496.633,3.898,7,1,12,101.49,0,-2.21,,,,-0.08,,,,,0.0592,10.87,,,,,,,39.81071706,-45.63190366,39.8107,60.2787,Inconclusive,0,-1.869665555,0,0,Inactive,Inactive,0,-7.759739299,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,7.526524546,,,,,,0,-18.41448732,,,,,,,0.7418765589,Oral,,"Both selexipag and its active metabolite are highly protein bound, approximately 99%.",,"On average, 35 L/hour.",Selexipag's terminal half life is 0.8-2.5 hours. The active metabolite's terminal half life is 6.2-13.5 hours.,,Gemfibrozil,Concomitant use of strong CYP2C8 inhibitors,Category B1,Not recommended,NA,,
Cinacalcet,"Antihypercalcemia, Antihyperparathyroidism","NOD-like receptor signaling pathway, Parathyroid hormone synthesis, secretion and action",CASR,calcium channel activator,,,7.7,pEC50,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,357.419,6.142,1,1,6,12.03,1,,,,,-0.38,,,,,-0.07555,18.38,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9797852907,Oral,,Approximately 93 to 97% bound to plasma proteins.,17.60 L/kg,18.30 mL/min/kg,19.90 hours,20 %,Eliglustat; etelcalcetide,Hyoersensitivity; decreased serum calcium,Category B3,Not recommended,NA,,
GUAIACOL,"Analgesic, Disinfectant",NA,CA2,,,,,,COc1ccccc1O,124.139,1.4008,2,1,1,29.46,0,,,,,,,,,0.2494,,,,,,,,,0,-15.06583958,0,0,Inactive,0,-59.48547569,0,0,Inactive,Inactive,0,3.329916268,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,6.257298955,,,,,,0,-13.15651465,,,,,,,0.4098765432,Oral,,,,,,,NA,NA,NA,NA,NA,,
ETHYLENEDIAMINE TETRACETATE TETRA-ETHANOLAMINE,NA,NA,,,,,,,OC(=O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O,536.58,-6.3216,14,12,15,340.68,0,-2.85,,,,-0.05,,,,,,2.523,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.70967467,,,,The volume of distribution of edetate calcium disodium is 0.19±0.10L/kg.[A204122],The mean clearance of edetate in 1 month olds is 54.6mL/min/1.73m2.[A204275] 2-17 year olds have a mean clearance of 113.9±24.4mL/min/1.73m2.[A204275],The half life of edetate calcium disodium is 20-60 minutes.[L12774],,NA,NA,NA,NA,NA,,
ALENDRONATE SODIUM,"Osteoporosis agent, Antiresorptive",Terpenoid backbone biosynthesis,"ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS",bone resorption inhibitor,,,,,NCCCC(O)(P(=O)(O)O)P(=O)(O)O,326.131,-6.7433,4,6,5,255.81,0,,,,,-0.19,,,,,,4.25,,,,,,,0,-6.120428415,0,0,Inactive,0,0.8439312517,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,3.186374568,,,,,,0,-1.654900642,,,,,,,0.9006643467,Oral,,,0.33 L/kg,2.60 mL/min/kg,3.10 hours,1 %,"Human parathyroid hormone, recombinant",Hypersensitivity; Hypocalcemia,Category B3,Not recommended,NA,,
RIZATRIPTAN BENZOATE,"Antimigraine, Vasoconstrictor","Neuroactive ligand-receptor interaction, Serotonergic synapse","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",serotonin receptor agonist,,,6.9,pKi,CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12.OC(=O)c1ccccc1,391.475,3.2966,5,2,6,87.04,0,-3.9,,,,0.07,,,,0.7991,,-3.916,,,,,,,25.11886432,-12.96989582,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,1.298560362,0,0,Inactive,Inactive,0,-0.0849137044,,,,,,0,-22.60824124,,,,,,,0.4482110862,Oral,,14%,1.90 L/kg,16 mL/min/kg,2.20 hours,45 %,"almotriptan
cabergoline
dihydroergotamine
dihydroergotamine intranasal
eletriptan
ergoloid mesylates
ergotamine
frovatriptan
methylergonovine
naratriptan
procarbazine
sumatriptan
sumatriptan intranasal
zolmitriptan","Hypersensitivity
Coronary artery vasospasm
History of stroke or transient ischemic attack
Ischemic bowel
Peripheral vascular disease
Basilar or hemiplegic migraine",Category B1,Use with caution,None,,
METAXALONE,Skeletal muscle relaxant,NA,,,,,,,O=C1NCC(COc2cc(C)cc(C)c2)O1,221.256,1.79064,3,1,3,47.56,1,-6.36,,,,0.12,,,,,0.2292,4.879,,,,,,,0,-10.21904745,0,0,Inactive,0,-28.56619021,0,0,Inactive,Inactive,0,0.5193065203,0,0,Inactive,0,-24.91748909,0,0,Inactive,Inactive,0,-2.741001034,,,,,,0,-7.591595644,,,,,,,0.4796506786,Oral,,,* 800 L,"* 68 +/- 50 L/h [Subjects received 1×400mg tablet under fasted conditions]
 * 66 +/- 51 L/h [Subjects received 2×400 mg tablets under fasted conditions]",9.2 (+/- 4.8) hours,,None,Hypersensitivity; renal/hepatic impairement,Category C,Not recommended,NA,,
DONEPEZIL HYDROCHLORIDE,Anti-Alzheimer's,"Glycerophospholipid metabolism, Cholinergic synapse",ACHE,acetylcholinesterase inhibitor,,,,,COc1cc2c(CC(CC3CCN(CC3)Cc3ccccc3)C2=O)cc1OC,415.961,4.7829,4,0,6,38.77,1,,,,,-0.2,,,,,0.173,18.24,,,,,,,39.81071706,-22.0683885,39.8107,75.6921,Inconclusive,0,4.254292812,0,0,Inactive,Inactive,39.81071706,-11.48366028,39.8107,38.3877,Inconclusive,0,-0.9717957086,0,0,Inactive,Inactive,0,-1.909780602,,,,,,0,-0.7433345907,,,,,,,0.6217082123,Oral,"Donepezil is slowly absorbed via the gastrointestinal tract after oral administration. Tmax is 3 to 4 hours with a bioavailability of 100% and steady-state concentrations are attained within 15 to 21 days of administration; The Tmax in one pharmacokinetic study determined a Tmax of 4.1 ± 1.5 hours. The Cmax of 5 mg donepezil tablets is estimated to be 8.34 ng/mL, according to the Canadian monograph. The AUC of 5 mg donepezil tablets has been determined to be 221.90-225.36ng hr/mL","96% protein-bound, with approximately 75% binding to albumin and approximately 21% binding to alpha-1-glycoprotein",The volume of distribution of donepezil is 11.8 ± 1.7 L/kg for a 5-mg dose and 11.6 ± 1.91 L/kg for a 10-mg dose. It is largely distributed in the extravascular compartments. Donepezil crosses the blood-brain barrier and cerebrospinal fluid concentrations at the above doses have been measured at 15.7%.[A182333] The volume of distribution at steady-state according to the FDA label for donepezil ranges from 12 - 16 L/kg.[L7916],"According to the FDA label, the average apparent plasma clearance of this drug is 0.13 – 0.19 L/hr/kg.[L7916] A 5 mg dose of donepezil in healthy patients was shown to have a plasma clearance of 0.110±0.02 L/h/kg.[L7952] In 10 patients diagnosed with alcoholic cirrhosis, showed a mean decrease in clearance by 20% when compared to the clearance in 10 healthy subjects. In 4 patients with severe renal impairment compared to 4 healthy subjects, no significant change in clearance was noted.[L7952]","The average elimination half-life of donepezil is about 70 hours according to the results of various studies and the FDA label for donepezil.[A182333,L7916]. One pharmacokinetic study determined the average terminal half-life to be 81.5±22.0 h[A182324]",99 %,None,Hypersensitivity,Category B3,Not recommended,NA,,
FAMPRIDINE,Multiple Sclerosis Agent,NA,,,,,,,Nc1ccncc1,94.117,0.6638,2,1,0,38.91,0,-6.59,,,,-0.05,,,,0.1168,0.1111,27.93,,,,,,,0,-151.4324653,0,0,Inactive,0,11.12891416,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-3.149196958,,,,,,0,-22.44053921,,,,,,,0.6824914587,Oral,"Tmax, immediate release form = 1 hour; Tmax, extended release form = 3.5 hours; Cmax, 10 mg extended release = 17.3 - 21.6 ng/mL",10 mg extended release = 1-3% protein bound,2.60 L/kg,9.30 mL/min/kg,3.60 hours,Relative bioavailability of 10 mg extended-release tablets compared to aqueous oral solution = 96%,NA,Hypersensitivity; history of seizures,Category C,Not recommended,NA,,
CYSTEAMINE HYDROCHLORIDE,Anti-urolithic (cysteine calculi),,"NPY2R, SST",tissue transglutaminase inhibitor,,,,,NCCS,113.613,0.2967,2,2,1,26.02,0,,,,,,,,,,0.253,,,,,,,,0,-66.28691718,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,7.089936575,0,0,Inactive,Inactive,0,6.788145336,,,,,,0,1.701907315,,,,,,,0.1283851555,Oral,"One pharmacokinetic study of adults with Cystic Fibrosis revealed a Cmax of 2.86 mg/L; The maximum plasma concentration after administration of cysteamine eye drops is unknown, however, it is likely to be considerably lower than oral administration; According to prescribing information, the AUC 0-12 h for the delayed-release oral tablets is 99.26 ± 44.2 μmol*h/L with a Cmax of 27.70 ± 14.99 μmol/L; The AUC 0-12 for the immediate-release tablets is 192.00 ± 75.62 μmol*h/L with a Cmax of 37.72 ± 12.10 μmol/L",52%,"Cysteamine has a volume of distribution of about 129 L, according to one pharmacokinetic study.[A218941] Prescribing information indicates a volume of distribution of 382 L for the delayed-release formulation and 198 L for the immediate-release preparation.[L15616]
 It is known to cross the blood-brain barrier.[A218946]",The plasma clearance of cysteamine is about 1.2 - 1.4 L/min.[L15616] One reference mentions a clearance of 89.9 L/h in patients with Cystic Fibrosis.[A218941],The half-life of cysteamine is about 3.7 hours.[A218941],,NA,Hypersensitivity,Category B3,Not recommended,NA,,
ZOLMITRIPTAN,"Antimigraine, Vasoconstrictor","Neuroactive ligand-receptor interaction, Seratonergic synapse","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",serotonin receptor agonist,,,8.9,pKi,CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12,287.363,1.9229,3,2,5,57.36,1,7.85,,,,0.24,,,,0.4913,0.1454,25.69,,,,,,,39.81071706,-62.03818209,39.8107,40.8308,Inconclusive,0,1.535060667,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-0.0490508012,,,,,,0,-1.18744114,,,,,,,0.326485837,Oral; intranasal,"The dosing kinetics are linear over a range of 2.5 to 50 mg with 75% of the eventual Cmax being attained within 1 hour of dosing. The median Tmax for the tablet form is 1.5 hours, while for the orally disintegrating tablet form, it is 3 hours.; The AUC across studies was in the range of 84.4-173.8 ng/mL*h while the Cmax was between 16 and 25.2 ng/mL",Zolmitriptan and its active N-desmethyl metabolite remain approximately 25% bound to plasma proteins over a concentration range of 10-1000 ng/mL,1.80 L/kg,6.70 mL/min/kg,3.60 hours,45 %,"almotriptan
bromocriptine
cabergoline
dihydroergotamine
dihydroergotamine intranasal
eletriptan
ergoloid mesylates
ergotamine
frovatriptan
methylergonovine
naratriptan
procarbazine
rizatriptan
sumatriptan
sumatriptan intranasal","Hypersensitivity
History of myocardial infarction
Ischemic or vasospastic artery disease
Peripheral vascular disease
Ischemic bowel disease",Category B3,Use with caution ,None,,
FUSIDIC ACID,Antibacterial,NA,,bacterial 30S ribosomal subunit inhibitor,,,,,CC(=CCC/C(=C1\[C@@H](OC(=O)C)C[C@@]2(C)[C@H]\1C[C@@H](O)C1[C@@]3(C)CC[C@@H](O)[C@@H](C)[C@@H]3CC[C@]21C)/C(=O)O)C,516.719,5.6661,5,3,5,104.06,10,6.87,,,,0.04,,,,,,8.77,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.413748275,Oral,,97 to 99%,,,Approximately 5 to 6 hours in adults.,91 %,NA,NA,Category C,Use with caution,NA,,
MEBEVERINE HYDROCHLORIDE,"Antispasmodic, Smooth muscle relaxant","Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse",CHRM1,acetylcholine receptor antagonist,,,,,COc1ccc(cc1)CC(C)N(CC)CCCCOC(=O)c1ccc(OC)c(OC)c1,466.018,5.0243,6,0,13,57.23,1,,,,,,,,,,0.1457,,,,,,,,11.22018454,-48.60249735,11.2202,68.1397,Active,0,16.57627023,0,0,Inactive,Inactive,39.81071706,-21.36239117,39.8107,73.2706,Inconclusive,0,-5.529893135,0,0,Inactive,Inactive,0,4.90429728,,,,,,0,-27.33328901,,,,,,,0.4428284855,,,,,,,,NA,NA,Category B2,Use with caution,NA,,
SUMATRIPTAN,"Antimigraine, Vasoconstrictor","Neuroactive ligand-receptor interaction, Serotonergic synapse","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7",serotonin receptor agonist,,,,,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,295.408,1.3212,3,2,6,65.2,0,-0.78,,,,-0.04,,,,,0.2609,15.35,,,,,,,0,0,0,0,Inactive,0,3.335673098,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,11.50400309,,,,,,0,-22.99016512,,,,,,,0.4741406996,Subcutaneous; Oral; Intranasal; Rectal,"A 6mg subcutaneous injection of sumatriptan reaches a Cmax of 69.5ng/mL (95% CI of 62.8-76.9ng/mL) with a Tmax of 0.17h (95% CI of 0.08-0.33h), an AUC of 9.0h*ng/mL (95% CI of 7.5-10.9h*ng/mL); A 25mg oral dose of sumatriptan reaches a Cmax of 16.5ng/mL (95% CI of 13.5-20.1ng/mL) with a Tmax of 1.50h (95% CI of 0.50-2.00h), an AUC of 8.7h*ng/mL (95% CI of 6.1-12.5h*ng/mL); A 20mg intranasal dose of sumatriptan reaches a Cmax of 12.9ng/mL (95% CI of 10.5-15.9ng/mL) with a Tmax of 1.50h (95% CI of 0.25-3.00h), an AUC of 7.4h*ng/mL (95% CI of 5.0-10.8h*ng/mL); A 25mg rectal dose of sumatriptan reaches a Cmax of 22.9ng/mL (95% CI of 18.4-28.6ng/mL) with a Tmax of 1.00h (95% CI of 0.75-3.00h), an AUC of 14.6h*ng/mL (95% CI of 11.3-18.8h*ng/mL)",14-21%,1.70 L/kg,19 mL/min/kg,1.70 hours,14 %,"almotriptan
bromocriptine
cabergoline
dihydroergotamine
dihydroergotamine intranasal
eletriptan
ergoloid mesylates
ergotamine
frovatriptan
methylergonovine
naratriptan
procarbazine
rizatriptan
zolmitriptan",Severe hepatic impairment; history of stroke; transient ischemic attack,Category B3,Use with caution ,None,,
FEXOFENADINE HYDROCHLORIDE,Antiallergic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",HRH1,histamine receptor antagonist,,,8,pKi,OC(CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1)c1ccc(cc1)C(C)(C)C(=O)O,538.128,5.9323,4,3,10,81,1,,,,,,,,,,0.1118,,,,,,,,6.309573445,-10.71723336,6.3096,32.3993,Inconclusive,0,8.438076289,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,9.02137978,0,0,Inactive,Inactive,0,6.428590678,,,,,,0,-3.817467539,,,,,,,0.592778335,Oral,"The Tmax following oral administration is approximately 1-3 hours; The steady-state AUCss(0-12h) and Cmax following twice daily dosing of 60mg are 1367 ng/mL.h and 299 ng/mL, respectively",60-70%,The volume of distribution is approximately 5.4-5.8 L/kg.[A1495],The oral clearance of fexofenadine is approximately 50.6 L/h and the renal clearance is approximately 4.32 L/h.[L10779],"The terminal elimination half-life is approximately 11-15 hours.[L10779,A1495]",70 %,None,Hypersensitivity,Category B2,Use with caution,None,,
LOFEXIDINE  HYDROCHLORIDE,Antihypertensive,Neuroactive ligand-receptor interaction,,adrenergic receptor agonist,,,8.36,pKi,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1,295.597,3.1842,3,1,3,33.62,1,,,,,-0.11,,,,0.03818,0.1853,14.75,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6035489167,Oral,"After oral administration of 0.8 mg of lofexidine, a maximal dose of 1.26 ng/ml is achieved after 3 hours",55% of administered dose,"Lofexidine has a volume of distribution of 300 L, indicating that it distributes readily into the tissues.[L2801]",The total elimination clearance following intravenous administration is 17.6 L/h.[L2801],The reported elimination half-life of lofexidine is 11 hours.[T55],90 %,None,None,NA,Use with caution,NA,,
ALFUZOSIN HYDROCHLORIDE,"Antidysuria, Antihypertensive","cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction","ADRA1A, ADRA1B, ADRA1D, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",adrenergic receptor antagonist,,,8.55,pKi,COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C1CCCO1,425.917,1.7725,8,2,8,111.83,1,,,,,,,,,,0.1086,,,,,,,,39.81071706,-19.93802843,39.8107,68.3852,Inconclusive,15.84893192,-53.08760273,0,0,Inactive,Inactive,39.81071706,-32.49831445,39.8107,111.466,Inconclusive,0,-63.21129643,0,0,Inactive,Inactive,0,5.573321162,,,,,,0,-10.16535314,,,,,,,0.6098294885,Oral,,82-90%,1.50 L/kg,5.90 mL/min/kg,4.80 hours,55 %,"atazanavir
ceritinib
chloramphenicol
cisapride
clarithromycin
cobicistat
darunavir
dronedarone
elvitegravir/cobicistat/emtricitabine/tenofovir DF
fluconazole
fosamprenavir
idelalisib
indinavir
itraconazole
ketoconazole
lefamulin
lopinavir
mifepristone
nefazodone
nelfinavir
ombitasvir/paritaprevir/ritonavir & dasabuvir
posaconazole
ritonavir
saquinavir
thioridazine
tipranavir
voriconazole","Hypersensitivity
Moderate to severe liver impairment",Category B2,Not recommended,None,,
FAMCICLOVIR,Antiviral,DNA synthesis/replication,,DNA polymerase inhibitor,,,,,CC(=O)OCC(COC(=O)C)CCn1cnc2cnc(N)nc12,321.337,0.541,9,1,7,122.22,0,-6.05,,,,-0.08,,,,0.2587,0.02613,9.899,,,,,,,0,-4.229773263,0,0,Inactive,0,-3.23016764,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-33.0731731,0,0,Inactive,Inactive,0,4.567967581,,,,,,0,-23.13213711,,,,,,,0.7183836702,Oral,,20-25%,* 1.08±0.17 L/kg [healthy male subjects following a single intravenous dose of penciclovir at 400 mg administered as a 1-hour intravenous infusion],"* 36.6 +/- 6.3 L/hr [healthy male]
 * 0.48 +/- 0.09 L/hr/kg [healthy male]",10 hours,77 %,Varicella virus vaccine live; zoster vaccine live,Hypersensitivity,Category B1,Use with caution,NA,,
NEFOPAM,Analgesic,NA,,cyclooxygenase inhibitor,,,,,CN1CCOC(c2ccccc2)c2ccccc2C1,253.345,3.238,2,0,1,12.47,1,-6.62,,,,-0.05,,,,,,29.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7812158604,,,,5.60 L/kg,12 mL/min/kg,5 hours,36 %,NA,NA,NA,Recommended,NA,,
ALMOTRIPTAN,Antimigraine,"Neuroactive ligand-receptor interaction, Seratonergic synapse","HTR1B, HTR1D",serotonin receptor agonist,,,8,pKi,CN(C)CCc1c[nH]c2ccc(cc12)CS(=O)(=O)N1CCCC1,335.473,2.1976,3,1,6,56.41,0,,,,,,,,,,0.03586,,,,,,,,0,2.282377859,0,0,Inactive,0,2.472437747,0,0,Inactive,Inactive,0,-10.60258012,0,0,Inactive,0,2.283325508,0,0,Inactive,Inactive,0,1.421262512,,,,,,0,-16.28695685,,,,,,,0.8485456369,Oral,,35%,2.20 L/kg,8.90 mL/min/kg,3.40 hours,70 %,"bromocriptine
cabergoline
dihydroergotamine
dihydroergotamine intranasal
eletriptan
ergoloid mesylates
ergotamine
frovatriptan
methylergonovine
naratriptan
procarbazine
rizatriptan
sumatriptan
sumatriptan intranasal
zolmitriptan","Hypersensitivity, severe hepatic or renal impairment, migraine prophylaxis",NA,Not recommended,None,,
VALACYCLOVIR HYDROCHLORIDE,Antiviral,DNA synthesis/replication,,,,,,,Nc1[nH]c(=O)c2ncn(COCCOC(=O)[C@@H](N)C(C)C)c2n1,360.802,-0.3758,9,3,7,151.14,1,,,,,-0.2,,,,,0.03059,6.38,,,,,,,39.81071706,-53.01135434,39.8107,66.7301,Inconclusive,0,0.2856305278,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-0.4495417646,,,,,,0,-15.30384158,,,,,,,0.8860010909,Oral; Intravenous,,13.5-17.9%,"Cerebrospinal fluid (CSF) penetration, determined by CSF/plasma AUC ratio, is approximately 25% for aciclovir and the metabolite 8-hydroxy-aciclovir (8-OH-ACV), and approximately 2.5% for the metabolite 9-(carboxymethoxy)methylguanine; In a study of immunocompromised pediatric patients, the volume of distribution of a 15 ml/kg dose of valacyclovir was 1.34 ± 0.65 L/kg","Renal clearance of acyclovir following the administration of a single 1 gram dose of valacylcovir to 12 healthy
 437 volunteers was approximately 255 ± 86 mL/min, which represents 42% of total acyclovir apparent plasma clearance [FDA label].",The plasma elimination half-life of acyclovir typically averaged 2.5 to 3.3 hours in several studies of valacyclovir in volunteers with normal renal function [FDA label].,The absolute bioavailability of acyclovir after administration of valacyclovir was measured at 54.5% ± 9.1% after the administration of a 1 gram oral dose of valacyclovir and a 350 mg intravenous (IV) acyclovir dose to 12 healthy subjects,None,Hypersensitivity,Category B3,Use with caution,NA,,
GRAMICIDIN (gramicidin A shown),Antibacterial,NA,,bacterial permeability inducer,,,,,OCCNC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC=O)C(C)C)C(C)C)C(C)C)C(C)C)Cc1c[nH]c2ccccc12)Cc1c[nH]c2ccccc12)Cc1c[nH]c2ccccc12)Cc1c[nH]c2ccccc12,1882.332,4.3723,17,21,53,548.99,14,21.89,,,,0.19,,,,,,17.26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.2468409332,,,,,,,,NA,NA,NA,NA,NA,,
EUGENOL,"Analgesic (dental), Disinfectant",NA,AR,androgen receptor antagonist,,,,,C=CCc1ccc(O)c(OC)c1,164.204,2.1293,2,1,3,29.46,0,,,,,0.02,,,,,0.2298,14.47,,,,,,,0,-31.5538779,0,0,Inactive,0,3.323220378,0,0,Inactive,Inactive,0,-34.51470758,0,0,Inactive,0,-4.625409364,0,0,Inactive,Inactive,0,-3.521465349,,,,,,0,-15.39638851,,,,,,,0.3390790054,,,,,,,,NA,NA,NA,NA,NA,,
ANTAZOLINE,Antiallergic,"Calcium signaling pathway, Neuroactive ligand-receptor interaction",HRH1,antihistamine,,,,,c1ccc(cc1)CN(CC1=NCCN1)c1ccccc1,265.36,2.6949,3,1,5,27.63,0,,,,,,,,,,0.1577,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.3891675025,,,,3.90 L/kg,19.67 mL/min/kg,2.29 hours,,NA,NA,NA,NA,NA,,
CAPSAICIN,Analgesic (topical),Neuroactive ligand-receptor interaction,"CFTR, TRPV1",TRPV agonist,,,,,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,305.418,3.7896,3,2,9,58.56,0,1.12,,,,-0.12,,,,,0.1538,26.63,,,,,,,0,-27.8973115,,,,0,-18.37713327,,,,,,,,,,,,,,,,0,-3.374946234,,,,,,0,-12.08591899,,,,,,,0.598152436,Oral,,,,,"Following oral ingestion of equipotent dose of 26.6 mg of pure capsaicin, the half life was approximately 24.9 ± 5.0 min [A32319]. Following topical application of 3% solution of capsaicin, the half-life of capsaicin was approximately 24 h [A32319]. The mean population elimination half-life was 1.64 h following application of a topical patch containing 179 mg of capsaicin [A32319].",,None,Hypersensitivity,NA,,None,,
HEXYLRESORCINOL,"Anthelmintic, Antiseptic",NA,TYR,,,,,,CCCCCCc1ccc(O)cc1O,194.274,3.2206,2,2,5,40.46,0,9.12,,,,0.01,,,,,0.2337,15.77,,,,,,,0,-266.743467,0,0,Inactive,0,-114.8138944,0,0,Inactive,Inactive,0.8912509381,-157.3408152,0.8913,93.7561,Active,39.81071706,-46.89155104,39.8107,90.6664,Inconclusive,Cytotoxic,0,-1.324503769,,,,,,0,-36.13365309,,,,,,,0.3343807691,,,,"Readily accessible data regarding the volume of distribution of hexylresorcinol is not available. Nevertheless, when hexylresorcinol is employed in its primary indication as a topical antiseptic or an oral anesthetic, it is generally accepted that pharmacokinetic considerations do not arise since the pharmacological action is local to the topically applied or oro-pharyngeal cavity area [L2735, F57, F58].","Readily accessible data regarding the clearance of hexylresorcinol is not available. Nevertheless, when hexylresorcinol is employed in its primary indication as a topical antiseptic or an oral anesthetic, it is generally accepted that pharmacokinetic considerations do not arise since the pharmacological action is local to the topically applied or oro-pharyngeal cavity area [L2735, F57, F58].","Readily accessible data regarding the half-life of hexylresorcinol is not available. Nevertheless, when hexylresorcinol is employed in its primary indication as a topical antiseptic or an oral anesthetic, it is generally accepted that pharmacokinetic considerations do not arise since the pharmacological action is local to the topically applied or oro-pharyngeal cavity area [L2735, F57, F58].",,NA,Hypersensitivity,Category C,No sufficient information is available,NA,,
CYCLIZINE,Anti-emetic,"Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels",,histamine receptor antagonist,,,8.35,pKi,CN1CCN(CC1)C(c1ccccc1)c1ccccc1,266.388,3.0234,2,0,3,6.48,0,-0.71,,,,0.01,,,,,0.1379,22.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5582926836,Oral,,,16.50 L/kg,14.50 mL/min/kg,13.53 hours,,None,"Not to be used in asthma, glaucoma, emphysema, chronic pulmonary disease, shortness of breath, difficulty in breathing or difficulty in urination due to enlargement of the prostate gland",Category B3,Not recommended,NA,,
PROCYCLIDINE HYDROCHLORIDE,"Antiparkinsonian, Skeletal muscle relaxant","Neuroactive ligand-receptor interaction, Cholinergic synapse",,acetylcholine receptor antagonist,,,8.34,pKi,OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1,323.908,4.3622,2,1,5,23.47,1,,,,,,,,,,0.2175,,,,,,,,39.81071706,-18.35942803,10,30.4467,Inconclusive,0,-0.0800553225,0,0,Inactive,Inactive,3.548133892,-71.05067187,3.5481,59.2229,Inconclusive,0,-7.828989871,0,0,Inactive,Inactive,0,22.30231787,,,,,,0,-10.54761591,,,,,,,0.2006018054,Oral,,100%,0.74 L/kg,0.86 mL/min/kg,12 hours,,NA,NA,Category A,NA,None,,
MESALAMINE,Anti-inflammatory,NA,,,,7.53E+03,5.12,pIC50,Nc1ccc(O)c(c1)C(=O)O,153.137,0.6726,3,3,1,83.55,0,-4.82,,,,-0.12,,,,0.3772,0.1964,7.437,,,,,,,31.6227766,-164.1986062,31.6228,32.152,Inconclusive,0,0,0,0,Inactive,Inactive,0,-5.192578285,0,0,Inactive,0,1.672845397,0,0,Inactive,Inactive,0,0.8431713774,,,,,,0,-18.29646341,,,,,,,0.5507846263,Oral,,43%,0.33 L/kg,9.30 mL/min/kg,0.61 hours,,None,Hypersensitivity; breastfeeding,NA,Use with caution,None,,
GUANETHIDINE,Antihypertensive,Synaptic vesicle cycle,SLC6A2,adrenergic inhibitor,,,,,NC(=N)NCCN1CCCCCCC1,198.314,0.73557,2,3,3,65.14,0,,,,,,,,,,0.1165,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5727181545,Oral,,,,* Renal cl=56 ml/min,1.5 days,20 %,NA,NA,Category A,NA,NA,,
GEMFIBROZIL,Antihyperlipidemic,"PPAR signaling pathway, Adipocytokine signaling pathway","LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1",lipoprotein lipase activator,,,4.23,pEC50,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,250.338,3.57324,2,1,6,46.53,0,3.12,,,,-0.17,,,,0.2785,0.05216,31.76,,,,,,,0,-18.64106194,0,0,Inactive,0,10.20667815,0,0,Inactive,Inactive,0,14.91858108,0,0,Inactive,0,-0.9400841229,0,0,Inactive,Inactive,0,-2.824674194,,,,,,0,-27.77773778,,,,,,,0.6340632601,Oral,"In healthy volunteers, a 900mg oral dose of gemfibrozil has a Cmax of 46±16µg/mL with a Tmax of 2.2±1.1h; In patients with chronic renal failure, gemfibrozil has a Cmax of 13.8±11.1µg/mL with a Tmax of 2.3±1.0h;  In patients with liver disease, gemfibrozil has a Cmax of 23.0±10.3µg/mL with a Tmax of 2.6±1.7h",99%,The volume of distribution of gemfibrozil is estimated to be 0.8L/kg.[A185807],The clearance of gemfibrozil is estimated to be 6.0L/h.[A185807],Gemfibrozil has a plasma half-life of 1.5 hours.[L8525] In patients with renal failure the half life is 2.4h and in patients with liver disease the half life is 2.1h.[A185813],98 %,Atorvastatin; elagolix; enzalutamide; fluvastatin; ombitasvir/paritaprevir/ritonavir & dasabuvir; pitavastatin; pravastatin; repaglinide; rosuvastatin; selexipag; simvastatin,Hypersensitivity;,Category B3,Not recommended,NA,,
SULFACETAMIDE,Antibacterial,Folate biosynthesis,,PABA antagonist,,,,,Nc1ccc(cc1)S(=O)(=O)NC(=O)C,214.246,0.0936,4,2,2,89.26,0,-3.73,,,,-0.23,,,,,0.2126,13.66,,,,,,,0,-21.97239218,0,0,Inactive,0,-36.12405438,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-79.78038325,0,0,Inactive,Inactive,0,-3.162920785,,,,,,0,-15.75799731,,,,,,,0.6468856512,,,,,,7-12.8 hours,,NA,NA,Category C,Not recommended,NA,,
BENZONATATE,Antitussive,NA,SCN5A,local anesthetic,,,,,COCCOCCOCCOCCOCCOCCOCCOCCOCCOC(=O)c1ccc(NCCCC)cc1,603.75,2.8346,12,1,32,121.4,0,,,,,,,,,,0.09156,,,,,,,,44.66835922,-177.1939654,0,0,Inactive,28.18382931,-1.062552279,0,0,Inactive,Inactive,39.81071706,-31.74484979,39.8107,108.881,Inconclusive,0,-5.035545993,0,0,Inactive,Inactive,0,-7.958129668,,,,,,0,-10.87862823,,,,,,,0.6790371113,Oral,The Cmax of benzonatate following oral administration of 100 mg in healthy Chinese volunteers was 1063 ± 460 ng/mL,,There is limited information on the volume of distribution of benzonatate.,There is limited information on the clearance of benzonatate.,The half life of benzonatate following oral administration of 100 mg in healthy Chinese volunteers was 1.01 ± 0.41 h.[A190267],,NA,Hypersensitivity,Category C,Use with caution,NA,,
DEXTROMETHORPHAN HYDROBROMIDE,Antitussive,"Neuroactive ligand-receptor interaction, Glutamatergic synapse","CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4","glutamate receptor antagonist, sigma receptor agonist",,,5.7,pIC50,COc1ccc2C[C@@H]3N(C)CC[C@]4(CCCC[C@H]34)c2c1,352.316,3.9613,2,0,1,12.47,3,,,,,,,,,,0.09056,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.6810431294,Oral,"A 30mg oral dose of dextromethorphan reaches a Cmax of 2.9 ng/mL, with a Tmax of 2.86 h, and an AUC of 17.8 ng*h/mL",60-70%,The volume of distribution of dextromethorphan is 5-6.7L/kg.[A215382],,Dextromethorphan has a half life of 3-30 hours.[A215382],11 %,Isocarboxazid; phenelzine; procarbazine; rasagiline; safinamide; selegiline; tranylcypromine,Serotonin syndrome,Category A,Not recommended,NA,,
CLIDINIUM BROMIDE,Anti-ulcerative,"Neuroactive ligand-receptor interaction, Cholinergic synapse, Gastric acid secretion","CHRM1, CHRM3",acetylcholine receptor antagonist,,,9.6,pKi,O=C(OC1C[N+]2(C)CCC1CC2)C(O)(c1ccccc1)c1ccccc1,432.358,-0.2915,3,1,4,46.53,3,,,,,-0.17,,,,,0.116,18.17,,,,,,,0,8.375349043,0,0,Inactive,0,16.10495424,0,0,Inactive,Inactive,0,0.7231716431,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,4.522916816,,,,,,0,-8.249829588,,,,,,,0.7257132041,,,,,,,,None,"Hypersensitivity
Glaucoma
Prostatic hypertrophy
Benign bladder neck obstruction
Severe respiratory depression",NA,NA,None,,
GLUCONOLACTONE,Chelating agent,NA,LCT,,,,,,OC[C@@H]1OC(=O)[C@@H](O)[C@H](O)[C@H]1O,178.14,-3.0132,6,4,1,107.22,4,13.48,,,,-0.12,,,,,,-1.322,,,,,,,0,-29.21710069,0,0,Inactive,0,3.367739276,0,0,Inactive,Inactive,0,1.362696216,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,4.157283012,,,,,,0,-29.17980059,,,,,,,0.5308183272,,,,,,,,NA,NA,NA,NA,NA,,
METAPROTERENOL,Bronchodilator,"Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction",ADRB2,adrenergic receptor agonist,,,,pKd (6.30),CC(C)NCC(O)c1cc(O)cc(O)c1,211.261,1.1292,4,4,4,72.72,1,-4.16,,,,0.18,,,,,-0.1316,11.26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7021328707,Oral,,,6.03 L/kg,14.07 mL/min/kg,6.41 hours,,NA,Hypersensitivity; Tachycardia,Category C,Use with caution,NA,,
METHENAMINE,"Antibacterial, Antiseptic",NA,,bacterial DNA inhibitor,,,,,C1N2CN3CN1CN(C2)C3,140.19,-1.0198,4,0,0,12.96,4,-2.65,,,,-0.12,,,,0.2897,0.2305,6.189,,,,,,,0,-77.16225557,0,0,Inactive,0,-6.87848719,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-1.354548881,0,0,Inactive,Inactive,0,1.60659242,,,,,,0,-8.194069743,,,,,,,0.5219227358,Oral,,,,70-90% of a single oral dose of methenamine is excreted unchanged in the urine within 24 hours. (1),Elimination half-life = 3-4 hours assuming normal renal function. (1),,NA,Hypersensitivity; Severe ranal/hepatic insufficiency,Category A,Use with caution,NA,,
ORPHENADRINE CITRATE,Skeletal muscle relaxant,"Calcium signaling pathway, Neuroactive ligand-receptor interaction, Glutamatergic synapse",,acetylcholine receptor antagonist,,,5.2,pIC50,CN(C)CCOC(c1ccccc1)c1ccccc1C.OC(=O)CC(O)(CC(=O)O)C(=O)O,461.511,2.41412,6,4,11,144.6,1,,,,,0.03,,,,,,7.93,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.4882948434,Oral; Parenteral,,95%,,,13-20 hours,,NA,"Hypersensitivity; Narrow-angle glaucoma; Pyloric/duodenal obstruction, BPH, stenosing peptic ulcers, cardiospasm (mega-esophagus), myasthenia gravis, obstructive uropathy, paralytic ileus, ulcerative colitis, toxic megacolon, achalasia",Category B2,Not recommended,NA,,
Uridine,NA,NA,"LSM6, TYMP",dopamine receptor agonist,,,,,O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1,244.203,-2.8519,7,4,2,124.78,4,3.88,,,,-0.22,,,,,,31.53,,,,,,,0,-156.6250647,,,,0,-2.34956466,,,,,,,,,,,,,,,,0,11.74001397,,,,,,0,-17.50930674,,,,,,,0.6949622337,Oral; Parenteral,,,,,,,NA,NA,NA,Use with caution,NA,,
MANNITOL,"Diuretic, Antihypertensive (intracranial, intraocular), Diagnostic aid (renal function determination)",NA,,,,,,,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,182.172,-3.5854,6,6,5,121.38,4,-29.88,,,,0.08,,,,,,13.85,,,,,,,0,0,,,,0,-0.046902475,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7042541035,Parenteral; Inhalation,13.71 μg/mL (inhalation),,0.24 L/kg,1.20 mL/min/kg,4.70 hours,7 %,NA,Hypersensitivity; Anuria; hypovolemia,Category B2,Use with caution,NA,,
Ondansetron,Anti-emetic,Serotonergic synapse,"HTR3A, HTR3B",serotonin receptor antagonist,,0.09,10.04,pIC50,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,293.37,3.12852,4,0,2,39.82,1,,,,,0.43,,,,,0.03849,21.17,,,,,,,39.81071706,-36.62229775,39.8107,63.8372,Inconclusive,0,10.04653386,0,0,Inactive,Inactive,0,10.20955714,0,0,Inactive,0,5.856562314,0,0,Inactive,Inactive,0,-1.764642754,,,,,,0,-19.86649003,,,,,,,0.5214406268,Oral; Parenteral,,"The plasma protein binding associated with ondansetron was documented as approximately 73% [F3181, F3184].",1.80 L/kg,5.80 mL/min/kg,3.40 hours,62 %,Apomorphine; dronedarone; lefamulin; posaconazole,Hypersensitivity,Category B1,Not recommended,NA,,
Inosine,Immunostimulant,NA,"PARP1, PNP",neurotrophic agent,,,,,O=c1[nH]cnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,268.229,-2.2689,8,4,2,133.49,4,,,,,,,,,-0.08895,,,,,,,,,0,1.986363677,0,0,Inactive,0,-4.685728235,0,0,Inactive,Inactive,0,-173.8535381,0,0,Inactive,0,-16.92537026,0,0,Inactive,Inactive,0,-4.486351467,,,,,,0,-23.27471509,,,,,,,0.9222222222,NA,,,,,,,NA,NA,NA,NA,NA,,
Carglumic Acid,Antihyperammonemic,NA,CPS1,carbamoyl phosphate synthase activator,,,,,NC(=O)N[C@@H](CCC(=O)O)C(=O)O,190.155,-1.0273,3,4,5,129.72,1,7.18,,,,-0.08,,,,,0.1387,-4.06,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.515083448,Oral,2.6 μg/mL,,The apparent volume of distribution was 2657 L (range: 1616-5797).,"The apparent total clearance was 5.7 L/min (range 3.0-9.7), the renal clearance was 290 mL/min (range 204-445), and the 24-hour urinary excretion was 4.5 % of the dose (range 3.5-7.5).",Median values for the terminal half-life was 5.6 hours (range 4.3-9.5).,0.3,NA,NA,Category B1,Not recommended,NA,,
L-Cycloserine,Antibacterial (tuberculostatic),"D-Alanine metabolism, Peptidoglycan biosynthesis",,,,2.62E+05,3.58,pIC50,N[C@H]1CONC1=O,102.093,-1.6249,3,2,0,64.35,1,,,,,,,,,1.42,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,-0.32265073,,,,,,0,-23.14784954,,,,,,,0.00987654321,Oral,,,,,,,NA,NA,Category C,Use with caution,NA,,
Galanthamine,Anti-Alzheimer's,"Glycerophospholipid metabolism, Cholinergic synapse",AChE,acetylcholinesterase inhibitor,,,7.21,pKi,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2,287.359,1.8503,4,1,1,41.93,3,1.53,,,,-0.14,,,,,0.2532,9.86,,,,,,,0,-0.4491893593,0,0,Inactive,0,-14.87576942,0,0,Inactive,Inactive,0,-70.42828382,0,0,Inactive,0,7.461606537,0,0,Inactive,Inactive,0,3.274323879,,,,,,0,-23.67345502,,,,,,,0.5097111789,Oral,"Following 10 hours of administration, the mean galantamine plasma concentrations were 82–97 µg/L for the 24 mg/day dose and 114–126 µg/L for the 32 mg/day dose",18%,2.30 L/kg,5.60 mL/min/kg,5.30 hours,99 %,NA,NA,Category B1,Not recommended,NA,,
Levetiracetam,Anticonvulsant,ECM-receptor interaction,"CACNA1B, SCN1A, SV2A",calcium channel blocker,,,6.1,pKi,CC[C@@H](C(N)=O)N1CCCC1=O,170.212,-0.1273,2,1,3,63.4,1,13.42,,,,-0.02,,,,0.008913,0.04659,4.118,,,,,,,0,-9.578996805,,,,0,2.194939496,,,,,,,,,,,,,,,,0,-1.14500812,,,,,,0,-15.83665762,,,,,,,0.6228891475,Oral,,<10%,0.60 L/kg,0.90 mL/min/kg,8.23 hours,99 %,None,Hypersensitivity,Category B3,Not recommended,NA,,
Voriconazole,Antifungal,Steroid biosynthesis,"CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1",cytochrome P450 inhibitor,,,8.73,pMIC,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,349.316,2.1769,6,1,5,76.72,2,-2.98,,,,-0.12,,,,0.00006668,0.166,9.578,,,,,,,0,-20.64709217,0,0,Inactive,0,-0.2529003423,0,0,Inactive,Inactive,0,-256.5160727,0,0,Inactive,0,-18.0515209,0,0,Inactive,Inactive,0,2.33931092,,,,,,0,-26.85638803,,,,,,,0.6880609937,Oral,Tmax is 1-2 hours with oral administration. When administered with a high-fat meal Cmax decreases by 34% and AUC by 24%. ,58%,2.20 L/kg,8.30 mL/min/kg,5.60 hours,96 %,Alfuzosin; carbamazepine; chloroquine; cobimetinib; conivaptan; dihydroergotamine; dihydroergotamine intranasal; efavirenz; eliglustat; ergoloid mesylates; ergonovine; ergotamine; finerenone; flibanserin; isavuconazonium sulfate; ivabradine; lefamulin; lomitapide; lonafarnib; lovastatin; lurasidone; methylergonovine; mirtazapine; naloxegol; phenobarbital; pimozide; quinidine; regorafenib; rifabutin; rifampin; ritonavir;sirolimus; St John's Wort; venetoclax; voclosporin,"HypersensitivitY; Patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption",Category B3,Not recommended,NA,,
Isosorbide mononitrate,Vasodilator (coronary),NA,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",nitric oxide stimulant,,,,,O=[N+]([O-])O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@H]12,191.139,-1.2782,6,1,2,91.06,4,-2.1,,,,-0.08,,,,0.4835,0.1018,17.33,,,,,,,0,-22.62457539,0,0,Inactive,0,1.126061146,0,0,Inactive,Inactive,0,-41.32001598,0,0,Inactive,0,-10.17061455,0,0,Inactive,Inactive,0,-3.59293739,,,,,,0,-21.11222957,,,,,,,0.5861945341,Oral,,5%,0.70 L/kg,2 mL/min/kg,4.10 hours,93 %,Avanafil; riociguat; sildenafil; tadalafil; vardenafil,Hypersensitivityl PDE-5 inhibitors,Category B2,Not recommended,NA,,
Deflazacort,Anti-inflammatory,Neuroactive ligand-receptor interaction,NR3C1,glucocorticoid receptor agonist,,,,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,441.524,2.5632,7,1,3,102.26,8,,,,,,,,,0.4333,0.3895,,,,,,,,0,3.004065231,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,3.886839808,0,0,Inactive,Inactive,0,-1.808185056,,,,,,0,-3.118318657,,,,,,,0.1539340243,Oral,One pharmacokinetic study determined an AUC (area under the curve) of 280 ng/ml · h,"The protein binding of the active metabolite of deflazacort is approximately 40%.[FDA label,A18759]",One study determined the volume of distribution to be 204 ± 84 L.[A18725],"114 ±27 L/h, according to one noncompartmental pharmacokinetic study.[A18725]
 
 The clearance of corticosteroids is enhanced in hypothyroid patients and increased in patients with hyperthyroidism. Dosing adjustments may be considered according to thyroid status.[FDA label] A study of corticosteroid clearance was performed in patients with a creatinine clearance of 15 mL/min or less, and determined that the active metabolite of deflazacort, 21-deflazacort was similar to that in patients with normal renal clearance.[FDA label]","The half-life of deflazacort ranges from 1.1 to 1.9 h [A18725,L6703]",68 %,mifepristone,Hypersensitivity ,NA,Not recommended ,None,,
Orlistat,Antiobesity,"Glycerolipid metabolism, Pancreatic secretion, Fat digestion and absorption","CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP",lipase inhibitor,,0.04,10.39,pIC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,495.745,6.8819,5,1,23,81.7,4,-3.03,,,,0.77,,,,,0.2509,37.35,,,,,,,0,0,0,0,Inactive,0,15.35785028,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,7.720739702,0,0,Inactive,Inactive,0,6.83501373,,,,,,12.58925412,-75.74974603,,,,,,,0.3476386206,Oral,,>99% bound to plasma proteins (lipoproteins and albumin were major binding proteins).,,,1 to 2 hours.,1 %,None,"Pregnancy
Chronic malabsorption syndrome
Cholestasis
Hypersensitivity",Category B1,Not recommended ,None,,
Moxidectin,Antiparasitic,NA,,chloride channel antagonist,,,,,CO/N=C1\C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C,639.83,5.7289,9,2,3,116.04,10,,,,,,,,,,0.3085,,,,,,,,10,-32.90467245,17.7828,66.6212,Inconclusive,0,-56.35418478,0,0,Inactive,Inactive,0,-86.46158184,0,0,Inactive,0,1.261892705,0,0,Inactive,Inactive,0,24.75448351,,,,,,3.548133892,-57.39317203,,,,,,,0.06419257773,Oral,plasma maximal concentration of 70.4 mg/kg was reached after 0.37 day with a reported AUC of 363.6 mcg/day/ml,This pharmacokinetic property in humans is unknown.[FDA label],Moxidectin presents a larger volume of distribution and mean residence time when compared to ivermectin. The reported volume of distribution is of 1.2 l/kg.[A33398],The apparent clearance of moxidectin is 3.5 L/hour.[A33428],Moxidectin reporter terminal half-life is 20.2 days.[A33398],,NA,None,NA,Use with caution ,NA,,
HYDROXYZINE PAMOATE,Anxiolytic,"Calcium signaling pathway, Neuroactive ligand-receptor interaction",HRH1,antihistamine,,,,,OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1.OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(=O)O)c1O,763.287,7.4473,8,5,12,151,1,-2.82,,,,-0.13,,,,,,29.11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7899524556,Oral,Maximum plasma concentration (Tmax) approximately 2 hours following administration.,,16.0 ± 3.0 L/kg,Clearance of hydroxyzine has been reported to be 31.1 ± 11.1 mL/min/kg in children and 9.8 ± 3.3 mL/min/kg in adults,"The half-life of hydroxyzine is reportedly 14-25 hours, and appears to be, on average, shorter in children (~7.1 hours) than in adults (~20 hours). Elimination half-life is prolonged in the elderly, averaging approximately 29 hours, and is likely to be similarly prolonged in patients with renal or hepatic impairment",,NA,Hypersensitivity; Prolonged QT interval,Category A,Use with caution,NA,,
Diazoxide,Antihypoglycemia,Insulin secretion,"ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3",potassium channel activator,,194000,3.71,pIC50,CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,230.676,1.8726,3,1,0,58.53,0,,,,,0,,,,0.02926,0.1379,11.11,,,,,,,0,-17.4302112,0,0,Inactive,0,0.1200289329,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-8.072316494,0,0,Inactive,Inactive,0,-2.097695373,,,,,,0,-8.958761539,,,,,,,0.5970386326,Oral,,>90%,0.21 L/kg,0.06 mL/min/kg,48 hours,90 %,NA,NA,Category C,Not recommended,NA,,
Cefaclor,Antibacterial,Peptidoglycan biosynthesis,,bacterial cell wall synthesis inhibitor,,,,,N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1,367.814,0.6213,5,3,4,112.73,3,34.21,,,,0.11,,,,0.6065,0.3978,74.81,,,,,,,0,-61.65771631,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.111376517,0,0,Inactive,Inactive,0,12.47723604,,,,,,0,-9.329917606,,,,,,,0.1863393358,Oral,,23.50%,,,0.6-0.9 hour,90 %,None,Hypersensitivity,Category B1,Use with caution,None,,
Methazolamide,Antiglaucoma,Proximal tubule bicarbonate reclamation,"CA1, CA12, CA14, CA2, CA4, CA7",carbonic anhydrase inhibitor,,14,7.85,pIC50,CC(=O)N=c1sc(S(N)(=O)=O)nn1C,236.278,-1.4238,6,1,1,107.41,0,-0.52,,,,0.21,,,,0.3518,,-19.29,,,,,,,0,-8.083392963,0,0,Inactive,0,-3.382568287,0,0,Inactive,Inactive,0,-39.94196852,0,0,Inactive,0,-20.16486471,0,0,Inactive,Inactive,0,2.272045862,,,,,,0,-19.55469442,,,,,,,0.4237128241,Oral,,55%,* 17 to 23 L,,14 hours,,None,"Hypokalemia, hyponatremia, hyperchloremic acidosis, cirrhosis, severe liver or renal impairment, adrenal gland failure",NA,Not recommended,None,,
Natamycin,"Antifungal, Antibacterial",NA,,fungal ergosterol inhibitor,,,,,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@H]3O[C@@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(=O)O,665.733,0.1197,13,7,3,230.99,14,3.99,,,,-0.01,,,,,,8.099,,,,,,,0,-123.8862319,0,0,Inactive,0,-6.075239446,0,0,Inactive,Inactive,0,-62.80907352,0,0,Inactive,0,0.8853136564,0,0,Inactive,Inactive,0,6.409062441,,,,,,0,-28.42120246,,,,,,,0.5136397951,Topical; oral,,,,,,,NA,Hypersensitivity,Category C,No sufficient information is available,NA,,
Aztreonam,Antibacterial,Peptidoglycan biosynthesis,,bacterial cell wall synthesis inhibitor,,,5.74,pIC50,C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O,435.44,-1.1725,10,4,7,201.58,2,1.89,,,,-0.06,,,,0.1281,0.135,7.203,,,,,,,0,-17.82056617,0,0,Inactive,0,3.745151877,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0.0655695203,0,0,Inactive,Inactive,0,2.365865255,,,,,,0,-21.80105294,,,,,,,0.5697772453,Oral; intramuscular,,"Serum protein binding averaged 56% and is independent of dose. Impaired renal function, 36 to 43%.",0.18 L/kg,1.50 mL/min/kg,1.50 hours,1 %,None,Hypersensitivity,Category B1,Use with caution,None,,
Nizatidine,Anti-ulcerative,"Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion",HRH2,histamine receptor antagonist,,,6.92,pKd,CN/C(=C\[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1,331.467,1.3225,8,2,10,83.33,0,-3.09,,,,0.04,,,,,,14.96,,,,,,,0,-59.26556635,0,0,Inactive,0,0.5872336092,0,0,Inactive,Inactive,0,-35.70183056,0,0,Inactive,0,2.352303281,0,0,Inactive,Inactive,0,-3.407845034,,,,,,0,-20.24463109,,,,,,,0.6209812273,Oral,,35%,1 L/kg,9.80 mL/min/kg,1.50 hours,70 %,None,"Hypersensitivity
Addison disease",Category B3,Not recommended,None,,
Mebendazole,Anthelmintic,NA,"TUBA1A, TUBB, TUBB4B",tubulin polymerization inhibitor,,,,,COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1,295.298,2.9722,4,2,3,84.08,0,13.81,,,,0.67,,,,0.1013,0.2334,31.63,,,,,,,1.412537545,-289.1873085,6.3096,35.2826,Inconclusive,11.22018454,-25.78230826,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-11.8704389,0,0,Inactive,Inactive,0,-14.3223736,,,,,,0.6309573445,-102.4539625,,,,,,,0.2932544245,Oral,,90-95%,1.20 L/kg,15 mL/min/kg,1.10 hours,22 %,None,Hypersensitivity,Category B3,Recommended,None,,
Nitrofurantoin,Antibacterial,NA,,DNA inhibitor,,,,,O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1,238.159,0.0735,6,1,3,118.05,0,21.5,,,,-0.2,,,,0.01764,0.1622,14.81,,,,,,,39.81071706,-75.70760384,0,0,Inactive,39.81071706,-12.15534096,0,0,Inactive,Inactive,39.81071706,-27.0930021,39.8107,97.9678,Inconclusive,39.81071706,-12.23198221,39.8107,41.9543,Inconclusive,Cytotoxic,0,-0.4997933271,,,,,,0,-18.3806785,,,,,,,0.5657409903,Oral,Nitrofurantoin reaches a Cmax of 0.875-0.963mg/L with an AUC of 2.21-2.42mg*h/L,90%,0.57 L/kg,9.70 mL/min/kg,0.97 hours,87 %,None,"Renal failure (anuria, oliguria, or CrCl <60 mL/min)
Pregnancy at term (38-42 weeks of gestation)
History of hepatic dysfunction/cholestatic jaundice with nitrofurantoin
Neonates (<28 days)
Hypersensitivity",Category A,Use with caution,None,,
Repaglinide,Antidiabetic,"ABC transporters, Insulin secretion","ABCC8, KCNJ11, PPARG",insulin secretagogue,,106,6.97,pIC50,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,452.595,5.2199,4,2,10,78.87,1,0.78,,,,0.08,,,,0.4307,0.06595,7.8,,,,,,,0,-21.37024321,0,0,Inactive,0,0.785861679,0,0,Inactive,Inactive,0,7.507815586,0,0,Inactive,0,4.746004284,0,0,Inactive,Inactive,0,19.26168264,,,,,,0,-43.60381092,,,,,,,0.5124231707,Oral; Intravenous,"Peak plasma concentrations are observed within 1 hour (range 0.5-1.4 hours). Maximal biological effect is observed within 3-3.5 hours and plasma insulin levels remain elevated for 4-6 hours. When a single 2 mg dose of repaglinide is given to healthy subjects, the area under the curve (AUC) is 18.0 - 18.7 (ng/mL/h)^3.",>98%,0.35 L/kg,7.80 mL/min/kg,0.87 hours,56 %,gemfibrozil,"Hypersensitivity
Diabetic ketoacidosis",Category C,Not recommended,None,,
Flunisolide,Anti-inflammatory,Neuroactive ligand-receptor interaction,NR3C1,cytochrome P450 inhibitor,,,9.1,pEC50,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,434.504,2.2747,6,2,2,93.06,9,-4.09,,,,-0.07,,,,0.0848,0.1937,12.51,,,,,,,0,-8.569648006,0,0,Inactive,0,-2.746354367,0,0,Inactive,Inactive,0,0.874872549,0,0,Inactive,0,-0.3590802621,0,0,Inactive,Inactive,0,-8.057623359,,,,,,0,-9.463560912,,,,,,,0.6005947259,,,Approximately 40% after oral inhalation,1.08 L/kg,9.50 mL/min/kg,1.68 hours,6.70 %,NA,NA,Category B3,Use with caution,None,,
Isosorbide dinitrate,Vasodilator (coronary),NA,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, NPR1",nitric oxide stimulant,,,,,O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-],236.136,-1.0622,8,0,4,123.2,4,-9.77,,,,0.11,,,,0.07718,,33,,,,,,,0,-141.3792057,0,0,Inactive,0,-9.50521202,0,0,Inactive,Inactive,0,1.320993622,0,0,Inactive,0,4.192086162,0,0,Inactive,Inactive,0,-1.774414316,,,,,,0,-25.48447319,,,,,,,0.660614621,Oral,,very low,1.90 L/kg,31 mL/min/kg,1.70 hours,22 %,"avanafil
riociguat
sildenafil
tadalafil
vardenafil","Hypersensitivity; Severe anemia, shock, markedly low blood pressure",Category B1,Use with caution,None,,
Cimetidine,Anti-ulcerative,"Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion","HRH2, SLC29A4, SLC47A1, SLC47A2",histamine receptor antagonist,,500,6.3,pIC50,CN/C(=N/CCSCc1nc[nH]c1C)NC#N,252.347,0.5974,4,3,5,88.89,0,-12.58,,,,-0.07,,,,0.01447,0.04968,17.13,,,,,,,0,-52.87610281,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,2.07875058,0,0,Inactive,Inactive,0,-1.200371473,,,,,,0,-3.749997116,,,,,,,0.819181253,Oral,,15-20%,1.20 L/kg,8.10 mL/min/kg,2.20 hours,60 %,Dofetilide; eliglustat; lomitapide; pimozide,Hypersensitivity,Category B1,Not recommended,NA,,
Furazolidone,"Antibacterial, Antiprotozoal",NA,,bacterial DNA inhibitor,,,,,O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1,225.16,0.9739,6,0,3,98.18,0,41.74,,,,-0.01,,,,,0.1034,19.33,,,,,,,0,-37.64639583,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,-3.270192183,0,0,Inactive,Inactive,0,-12.59640374,,,,,,0,-33.75129087,,,,,,,0.4398669923,Oral,,,,,10 minutes,,NA,NA,NA,NA,None,,
Belumosudil,Autoimmune disease treatment,Chemokine signaling pathway,ROCK2,Rho-associated kinase inhibitor,,,,,CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1,452.518,4.8201,6,3,7,104.82,0,-8.64,,,,1.65,,,,,,-34.99,,,,,,,0,-115.9486971,,,,12.58925412,-69.41061446,,,,,,,,,,,,,,,,0,-4.624684727,,,,,,0,-24.79763519,,,,,,,0.5187219347,Oral,,,,,,,NA,NA,,Not recommended,NA,,
Tepotinib (EMD 1214063),Antineoplastic,"Ras signaling pathway, PI3K-Akt signaling pathway, ",MET,tyrosine kinase inhibitor,,,,,NCc1cccc(c1)c1ccc(=O)n(Cc2cccc(c2)c2ncc(OCC3CCN(C)CC3)cn2)n1,492.583,4.00788,8,0,7,96.93,0,,,,,,,,,,,,,,,,,,39.81071706,-9.879535887,,,,0,-99.1826676,,,,,,,,,,,,,,,,12.58925412,76.02991964,10,72.8017,Inconclusive,,,0,-15.09034285,12.5893,89.2776,Inconclusive,Cytotoxic,,,0.4615384615,Oral,,,,,,,NA,NA,,Not recommended,NA,,
Telotristat,Antidiarrheal,"Tryptophan metabolism, Serotonergic synapse

",TPH,Tryptophan hydroxylase inhibitor,,,,,Cc1ccn(-c2cc(Cl)ccc2[C@@H](Oc2cc(-c3ccc(C[C@H](N)C(=O)O)cc3)nc(N)n2)C(F)(F)F)n1,546.937,4.51012,8,3,8,142.17,2,,,,,,,,,,-0.05214,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0.6938088901,,,,,,0,1.602287202,,,,,,,0.9548645938,Oral,,,,,,,"doravirine
lonafarnib",NA,Category B3,Not recommended,NA,,
Fexinidazole,Antiparasitic,,,,,,,,CSc1ccc(OCc2ncc([N+](=O)[O-])n2C)cc1,279.321,2.6292,6,0,5,70.19,0,19.95,,,,0.02,,,,,0.1901,14.15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.3282026362,Oral,,,,,,,lonafarnib,"Hypersensitivity
Hepatic impairment",NA,NA,NA,,
Umbralisib,Antineoplastic,"Inositol phosphate metabolism, Chemokine signaling pathway, FoxO signaling pathway, Phosphatidylinositol signaling system, PI3K-Akt signaling pathway, Wnt signaling pathway, Hedgehog signaling pathway, B cell receptor signaling pathway
","PIK3CD, CSNK1E ",,,,,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,571.559,6.6627,8,1,6,109.06,1,24.32,,,,-0.05,,,,,,19.1,,,,,,,0,2.26298998,,,,0,-0.8897298386,,,,,,,,,,,,,,,,0,10.98489712,,,,,,0,-8.664528874,,,,,,,0.418878454,Oral,,,,,,,NA,NA,NA,NA,NA,,
ZILEUTON,Antiasthmatic,Arachidonic acid metabolism,ALOX5 ,Arachidonate 5-lipoxygenase inhibitor,,,,,ON(C(=O)N)C(C)c1cc2ccccc2s1,236.296,2.7322,3,2,2,66.56,1,,,,,0.03,,,,-0.00439,0.2291,9.14,,,,,,,6.309573445,-18.63245659,6.3096,38.1681,Inconclusive,0,15.53924379,0,0,Inactive,Inactive,0,0,0,0,Inactive,0,0,0,0,Inactive,Inactive,0,-1.35771927,,,,,,0,-26.24428017,,,,,,,0.5023437666,Oral,,,* 1.2 L/kg,* Apparent oral cl=7 mL/min/kg,2.5 hours,,flibanserin,"Hypersensitivity
Liver disease",NA,Not recommended,NA,,
Dydrogesterone,Menstruation disorder agent,"Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway


",NR3C3 (PGR),Progesterone receptor agonist,,,6.9,pKi,CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,312.453,4.4995,2,0,1,34.14,6,,,,,0.63,,,,0.5447,0.01426,17,,,,,,,0.7079457844,-50.03005857,0.7079,34.9741,Inconclusive,0,-3.848148201,0,0,Inactive,Inactive,39.81071706,-24.5126191,39.8107,84.0755,Inconclusive,0,3.135703538,0,0,Inactive,Inactive,0,-1.381872808,,,,,,0,-6.752608153,,,,,,,0.4270469993,Oral,,,,,"Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours",28 %,NA,NA,Category B3,Not recommended,NA,,